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1. INTRODUCTION 
 
CANCER 
Cancer is a class of disease in which a group of cells display 
uncontrolled growth, invasion that intrudes upon and destroys the 
adjacent tissues, and sometimes metastasis, or spreading to the other 
locations in the body via lymph or blood. 
 
Classification 
  
Types of tumour (National Cancer Institute 2008): 
Cancers are classified by the type of cell that the tumor resembles 
and is therefore presumed to be the origin of the tumor. These types 
include: 
• Carcinoma: Cancer derived from epithelial cells. This group 
includes many of the most common cancers, including those of 
the breast, prostate, lung and colon. 
• Sarcoma: Cancer derived from connective tissue, or 
mesenchymal cells. 
• Lymphoma and leukemia: Cancer derived from hematopoietic 
(blood-forming) cells. 
• Germ cell tumor: Cancer derived from pluripotent cells. In adults 
these are most often found in the testicle and ovary, but are more 
common in babies and young children. 
• Blastoma: Cancer derived from immature "precursor" or 
embryonic tissue. These are also commonest in children. 
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Cancers are usually named using -carcinoma, -sarcoma or -
blastoma as a suffix, with the Latin or Greek word for the organ or 
tissue of origin as the root. 
 
Types of malignancies: 
      
     Type of hematological malignancy: 
     (National Cancer Institute, 2008) 
 
  
     Leukemias   
    Acute lymphoblastic leukemia (ALL)   
    Acute myelogenous leukemia (AML)   
    Chronic lymphocytic leukemia (CLL)  
    Small lymphocytic lymphoma (SLL)    
    Chronic myelogenous leukemia (CML)   
    Acute monocytic leukemia (AMOL)   
    Other leukemias   
 
     Lymphomas 
 
  
    Hodgkin's lymphomas (all four subtypes)   
    Non-Hodgkin's lymphomas (all subtypes)   
 
  Myelomas 
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Indian Estimated age-standardized incidence and mortality rates: both 
sexes (World Health Organization-International Agency for Research 
on Cancer; 2008) 
 
 
FIGURE: 1 
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Table: 1 
Estimated incidence, mortality and 5-year prevalence: 
both sexes ASR (W) and proportions per 100,000 
 
             
Cancer 
Incidence Mortality 5-year prevalence 
Number ASR (W) Number ASR (W) Number ASR (W) 
Lip, oral 
cavity 69820 7.5 47653 5.2 107690 13.4 
Nasopharynx 3333 0.3 2412 0.2 8410 1.0 
Other 
pharynx 45271 5.0 39346 4.3 66391 8.2 
Oesophagus 48099 5.3 43351 4.8 25610 3.2 
Stomach 35059 3.8 33564 3.6 25257 3.1 
Colorectum 36476 3.9 25690 2.8 49122 6.1 
Liver 20144 2.2 18043 2.0 9639 1.2 
Gallbladder 17262 1.9 10279 1.1 21038 2.6 
Pancreas 8960 1.0 7766 0.9 5052 0.6 
Larynx 23058 2.5 14794 1.7 45753 5.7 
Lung 58567 6.6 52269 5.9 26994 3.3 
Melanoma of 
skin 945 0.1 483 0.1 2394 0.3 
Breast 115251 22.9 53592 11.1 315679 80.6 
Cervix uteri 134420 27.0 72825 15.2 338010 86.3 
Corpus uteri 8772 1.9 4851 1.1 32013 8.2 
Ovary 28080 5.7 19558 4.1 57796 14.8 
Prostate 14630 3.7 10422 2.5 48892 11.8 
Testis 3864 0.6 1665 0.3 12980 3.1 
Kidney 8900 0.9 5733 0.6 18356 2.3 
Bladder 14812 1.7 8203 1.0 33590 4.2 
Brain, nervous 
system 21835 2.1 17941 1.8 31781 3.9 
Thyroid 12899 1.2 3029 0.3 51521 6.4 
Hodgkin 
lymphoma 7371 0.7 3587 0.4 11899 1.5 
Non-Hodgkin 
lymphoma 23718 2.4 16243 1.7 27031 3.3 
Multiple 
myeloma 6789 0.8 5941 0.7 11602 1.4 
Leukaemia 33307 3.0 26282 2.5 24658 3.1 
All cancers 948858 98.5 633455 68.0 1705085 211.4 
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Signs and symptoms 
 
Symptoms of cancer metastasis depend on the location of the 
tumor. 
 
Cancer symptoms can be divided into three groups: 
 
 Local symptoms are restricted to the site of the primary cancer. 
They can include lumps or swelling (tumor), hemorrhage 
(bleeding from the skin, mouth or anus), ulceration and pain. 
Although local pain commonly occurs in advanced cancer, the 
initial swelling is often painless. 
 
 Metastatic symptoms are due to the spread of cancer to other 
locations in the body. They can include enlarged lymph nodes 
(which can be felt or sometimes seen under the skin), 
hepatomegaly (enlarged liver) or splenomegaly (enlarged 
spleen) which can be felt in the abdomen, pain or fracture of 
affected bones, and neurological symptoms. 
 
 Systemic symptoms occur due to distant effects of the cancer 
that are not related to direct or metastatic spread. Some of these 
effects can include weight loss (poor appetite and cachexia), 
fatigue, excessive sweating (especially night sweats), anemia 
(low blood count) and other specific conditions termed 
paraneoplastic phenomena. These may be mediated by 
immunological or hormonal signals from the cancer cells. 
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RISK FACTORS (P. N. Bennett et al., 2001): 
 
The most common cancer risk factors are: 
• Genetic predisposition -- Certain types of cancer, such as colon 
and breast cancer often run in families. It is only the predisposition 
to cancer that is inherited.  
• Estrogen exposure (women) -- A woman is at increased risk for 
some gynecological cancers (e.g. breast or uterine cancer) if her 
system is exposed to too much estrogen, as this stimulates cell 
proliferation in these tissues. 
• Ionizing radiation -- Overexposure to ionizing radiation, such as 
X rays and nuclear radiation can cause DNA injury that may lead 
to cancer.  
• Ultraviolet radiation – It is the radiation from the sun. Ultraviolet 
B (UVB) rays damage cell DNA and cause 90 percent of all skin 
cancers.  
• Carcinogenic chemicals -- Chemical carcinogens such as asbestos, 
benzene, formaldehyde, and diesel exhaust are dangerous in high 
concentrations.  
• Tobacco smoke -- Smoking causes 30 percent of all cancer deaths 
in the United States, making tobacco smoke the single most lethal 
carcinogen. Smoking can cause cancers in the lungs and other 
organs.  
• Alcohol -- People who drink alcohol heavily have a higher risk of 
mouth, throat, esophagus, stomach, and liver cancer.  
• Carcinogenic foods -- There are certain foods that contain 
carcinogens. Foods that should be limited include salted, pickled, 
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and smoked foods, such as pickles or smoked fish, and meats 
treated with nitrites. 
• Free radicals are dangerous, highly reactive chemical compounds 
that can damage DNA and lead to cancer.  
 
Table: 2 
List of Carcinogens and the Cancers 
 
 
Agent Cancer Type 
Benzo [a]-pyrene (Tobacco) Lung 
Alcohol Mouth, Pharynx, Larynx, Espohagus 
Dietary Fat Breast 
Asbestos Respiratory-tract, Pleural and Peritoneal Mesothelioma 
Fermented Foods Stomach 
Estrogens Endometrial, Ovarian, Breast 
UV Light Skin 
X-Radiation and 
Gamma Radiation 
Leukemia, Thyroid, Breast, Lung, 
Mouth, Stomach, Colon, Bladder, 
Ovarian, Skin, Central Nervous 
System 
Tamoxifen Endometrial 
In-Utero Diethylstilbestrol Childhood Cancer 
Transabdominal Radiation Childhood Cancer 
Aflatoxin Liver 
Soot, Coal (Chimney Sweeping) Scrotal 
Nickel (Nickel Refining) Lung, Nasal 
Wood Dust (Woodworking) Nasal 
Cr(VI) (Leatherworking) Lung 
Mustard Gas Respiratory-tract, Lung  
2-napthylamine Bladder 
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Origins of Cancer 
All cancers begin in cells, the body's basic unit of life. To 
understand cancer, it's helpful to know what happens when normal 
cells become cancer cells. The body is made up of many types of cells. 
These cells grow and divide in a controlled way to produce more cells 
as they are needed to keep the body healthy. When cells become old or 
damaged, they die and are replaced with new cells. 
However, sometimes this orderly process goes wrong. The 
genetic material (DNA) of a cell can become damaged or changed, 
producing mutations that affect normal cell growth and division. When 
this happens, cells do not die when they should and new cells form 
when the body does not need them. The extra cells may form a mass of 
tissue called a tumor. 
Not all tumors are cancerous; tumors can be benign or malignant. 
• Benign tumors aren't cancerous. They can often be removed, 
and, in most cases, they do not come back. Cells in benign 
tumors do not spread to other parts of the body.  
• Malignant tumors are cancerous. Cells in these tumors can 
invade nearby tissues and spread to other parts of the body. The 
spread of cancer from one part of the body to another is called 
metastasis. 
Some cancers do not form tumors. For example, leukemia is a cancer of 
the bone marrow and blood (Robbins’s et al., 1999). 
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Pathophysiology 
Cancers are caused by a series of mutations. Each mutation alters 
the behavior of the cell. Cancer is fundamentally a disease of failure of 
regulation of tissue growth. In order for a normal cell to transform into 
a cancer cell, the genes which regulate cell growth and differentiation 
must be altered.  
The affected genes are divided into two broad categories. 
Oncogenes are genes which promote cell growth and reproduction. 
Tumor suppressor genes are genes which inhibit cell division and 
survival.  
Malignant transformation can occur through the formation of 
novel oncogenes, the inappropriate over-expression of normal 
oncogenes, or by the under-expression or disabling of tumor 
suppressor genes. Typically, changes in many genes are required to 
transform a normal cell into a cancer cell.  
The Stages of the Cell Cycle 
The stages of the cell cycle are depicted below. 
• G1 and G2 stand for 'gaps'. This refers to the fact that nothing 
very obvious is occurring in the nucleus of the cells during these 
stages. The cells are actually very active. They are growing and 
preparing to divide.  
• S stands for synthesis. This is the phase of the cell cycle in which 
the DNA is copied or replicated.  
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• M stands for mitosis. This is the stage of the cell cycle in which 
the cell actually divides into two daughter cells. 
DNA replication occurs in the synthesis or S phase of the Cell 
Cycle. Every chromosome is copied with high fidelity in a process that 
involves a large number of enzymes (Sawant et al., 2003). 
Characteristics of Cancer Cells 
There are numerous changes that must occur for a normal cell to 
become a cancer cell.  Additional changes are needed for that single cell 
to form a tumor and then for that tumor to grow and spread (Hanahan 
D., 2000).    
• Growth Without 'GO' Signals  
• Failure to Respond to 'STOP' Signals  
• Unlimited Number of Cell Divisions  
• Avoidance of Cell Death  
• Angiogenesis  
• Tissue Invasion and Metastasis  
 
TYPES OF CANCER 
 
The common types of Cancers are, 
¾ Breast  
¾ Cervical  
¾ Colon & Rectal (Colorectal)  
¾ Leukemia  
¾ Liver  
¾ Lung  
¾ Lymphoma  
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¾ Multiple Myeloma  
¾ Pancreatic  
¾ Prostate  
¾ Skin  
¾ Stomach (Gastric) 
 
Breast Cancer: Introduction 
Breast cancer ranks as one of the leading cancer types in the 
number of new cases diagnosed. In 2010 the American Cancer Society 
estimates approximately 209,060 new cases of breast cancer will be 
diagnosed and 40,230 deaths due to breast cancer will occur in the 
United States (American Cancer Society Cancer Facts and Figures 
2010).  
 
Breast Cancer: Types  
There are several different kinds of breast cancer. However, the 
majority of breast cancer cases are classified as either in situ or invasive 
(Simpson PT et al., 2003).  
 
Carcinoma In Situ (CIS) 
• Lobular Carcinoma In Situ (LCIS)  
Lobular carcinoma in situ describes breast cancer that is confined 
to the milk-producing glands (lobules) of the breast.  
• Ductal Carcinoma In Situ (DCIS)  
Ductal carcinoma in situ describes breast cancer that is confined 
to the milk ducts of the breast.  
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Invasive Breast Carcinoma (IBC) 
• Invasive Lobular Carcinoma (ILC)  
Invasive lobular carcinoma develops in the milk-producing 
glands (lobules) of the breast.  
• Invasive Ductal Carcinoma (IDC) 
Invasive ductal carcinoma is the most common type of invasive 
breast cancer, responsible for almost 85% of cases.   
 
Breast Cancer: Risk Factors (Singletary SE et al., 2003) 
 Prior History of Breast Disease  
 Family History of Breast Disease  
 Age  
 Race  
 Reproductive and Menstrual History 
 Hormone Replacement Therapy  
 Exposure to Diethylstilbestrol 
 Radiation Exposure  
 Dietary Factors 
 
Breast Cancer: Symptoms  
The American Cancer Society lists the following symptoms 
associated with breast cancer: 
 Presence of a lump or thickening in the breast;  
 Swelling, dimpling, redness, or soreness of skin;  
 Change in shape or appearance of the nipple; and  
 Nipple discharge. 
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Breast Cancer: Detection and Diagnosis 
The American Cancer Society has published guidelines for 
screening for women with a normal risk for breast cancer.  
 
Detection 
 Breast Exam  
 Mammography  
 Ultrasound  
 Breast MRI  
Diagnosis 
 Fine Needle Aspiration  
 Core Needle Biopsy  
 Breast Tumor Pathology  
 Sentinel Lymph Node Biopsy  
 
Breast Cancer: Treatment 
 
The National Comprehensive Cancer Network (NCCN) lists the 
following treatments for breast cancer: 
 
• Surgery  
• Radiation Therapy  
• Chemotherapy  
• Hormone Therapy  
 SERMs  
• Monoclonal Antibody Therapy  
 Herceptin 
• Prophylactic Mastectomy 
• Breast Conservation Therapy( BCT)  
• Mastectomy 
 
 
 
 
 
 
 
Introduction  
 
14 
 
Cervical Cancer: Introduction 
Cervical cancer forms in the interior lining of the cervix, the 
junction of the vagina and uterus. In 2010 the American Cancer Society 
estimates 12,200 women will be diagnosed with invasive cervical cancer 
and 4,210 will die of the disease in the United States (Schiffman M et 
al., 2007) 
 
Types of Cervical Cancer (National Cancer Institute) 
The two types of cervical cancer are  
• squamous cell carcinoma  
• adenocarcinoma 
 
Both squamous cell and adenocarcinoma begin in the cells that 
line hollow organs, but squamous cells have a thin, flat appearance 
while adenocarcinomas involve cells with secretory functions. 
Squamous cell carcinoma is far more common and makes up 
approximately 90% of cervical carcinoma cases. 
 
Cervical Cancer: Risk Factors (Khan MJ et al., 2005) 
 Human Papillomavirus (HPV) Infection  
 Family History of Cervical Cancer  
 Age  
 Sexual and Reproductive History  
 Socioeconomic Status  
 Smoking  
 HIV Infection  
 In Utero DES Exposure  
 Long-term use of oral contraceptives  
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Cervical Cancer: Symptoms (Petignat P et al., 2007)  
          Typically, early cervical cancer is asymptomatic, but abnormal 
vaginal bleeding can occur once the cancer becomes invasive. 
 
Cervical Cancer: Detection and Diagnosis 
Detection: 
 CA-125 for detecting ovarian cancer.  
 Pap smear for detecting cervical and vaginal cancer.  
 Ultrasound for detecting ovarian and uterine cancer.  
Diagnosis: 
 Human Papillomavirus Infection  
 Cervical Intraepithelial Neoplasia (CIN) 
 Colposcopy  
 Biopsy  
 
Cervical Cancer: Pathology Report and Staging 
Cervical intraepithelial neoplasia (CIN) is an abnormal 
condition that is detectable by Pap smears and other cervical exams. 
CIN is the growth of abnormal cells in the lining of the cervix. The 
image shows microscopic images of normal cervical tissue, CIN 1, CIN 
2 and CIN 3. 
  
Cervical Cancer: Treatment (Petignat P et al., 2007) 
 Surgery  
 Radiation  
 Chemotherapy  
 Cervical Cancer Vaccine 
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Colon and Rectal Cancer: Introduction 
Colon cancer and rectal cancer, collectively known as colorectal 
cancer, have many similar characteristics. Colorectal cancer is currently 
the third most common cancer in both men and women. 
 In 2010, the American Cancer Society estimates that there will be 
approximately 142,570 new cases diagnosed and 51,370 deaths due to 
colorectal cancer in the United States. (Cancer Facts and Figures 2010. 
American Cancer Society) 
 
Colon and Rectal Cancer: Risk Factors  
 Family History of Colorectal Cancer  
 Age  
 Diets rich in red or processed meat  
 Excessive drinking of alcohol  
 Obesity  
 Smoking  
 
The two major colorectal cancer susceptibility syndromes are called  
• Familial adenomatous polyposis (FAP)- Figure shows the mucosal 
surface of the colon carpeted with numerous early adenomas. 
• Hereditary non-polyposis colorectal cancer (HNPCC) 
 
Colon and Rectal Cancer: Symptoms 
 Bleeding in the rectum  
 Bloody stools  
 A change in bowel habits  
 Cramps in the colorectal region  
 Anemia from the blood loss  
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Colon and Rectal Cancer: Detection and Diagnosis (Lemon Set al ., 
2001) 
 
 Sigmoidoscopy every 5 years, or  
 Colonoscopy every 10 years, or  
 Double contrast barium enema every 5 years, or  
 CT colonography (virtual colonoscopy) every 5 years  
 
Colon and Rectal Cancer: Treatment 
 Surgery  
 Radiation Therapy  
 Chemotherapy  
 
Lung Cancer: Introduction  
Lung cancer currently ranks as the leading cause of cancer 
related deaths in men and women. 2010, the American Cancer Society 
estimates 222,520 new cases will be diagnosed and 157,300 deaths due 
to lung cancer will occur in the United States (Alberg AJ et al., 2005) 
 
Types of Lung Cancer 
Lung cancer is divided into 2 main types: 
• Small cell lung cancer (SCLC)  
• Non-small cell lung cancer (NSCLC) 
 
Small cell lung cancer (SCLC) accounts for about 14% of all lung 
cancers.Also known as oat cell carcinoma or small cell undifferentiated 
carcinoma, SCLC tends to be aggressive. 
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Non-small cell lung cancer (NSCLC) is divided into three categories, 
based on appearance and other characteristics of the cancerous cells: 
 Squamous cell carcinoma (SCC) 
 Adenocarcinoma 
 Large Cell Carcinoma (LCC) 
 
Lung Cancer: Risk Factors  
 Smoking (especially cigarettes, pipes, cigars)  
 Secondhand smoke and air pollution  
 Family history  
 Radon  
 Asbestos  
 Metals like chromium, cadmium, arsenic  
 Chronic lung diseases such as tuberculosis  
 
Lung Cancer: Symptoms 
 Persistent cough  
 Sputum streaked with blood  
 Chest pain  
 Voice change  
 Recurrent pneumonia or bronchitis  
 
Lung Cancer: Detection and Diagnosis (Ganti AK et al., 2006) 
 chest x-ray  
 chest CT (computer tomography) scan,  
 bronchoscopy (insertion of a tube into the bronchi), and  
 Sputum cytology (examination of cells in the phlegm). 
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Lung Cancer: Treatment 
The National Comprehensive Cancer Network (NCCN) lists the 
following; 
 Surgery  
 Radiation Therapy  
 Chemotherapy   
 
Pancreatic Cancer: Introduction 
Pancreatic cancer currently carries with it a poor prognosis. The 
American Cancer Society estimates that in the year 2010, 43,140 people 
will be diagnosed with pancreatic cancer and there will be 36,800 
deaths (Ghaneh P et al., 2007).  
       
Types of Pancreatic Cancer 
The type of cancer is based on the cell type and location of the 
tumor in the pancreas. More than 95% of pancreatic cancers are 
adenocarcinomas of the exocrine pancreas. 
 
• Adenocarcinoma - this is cancer of the exocrine cells that line the 
pancreatic ducts. The majority of pancreatic cancers are this 
type.  
• Cystic Tumors - tumors that cause fluid filled sacs in the 
pancreas. Most are benign.  
• Acinar Cell Cancers - tumors that form on the ends of the 
pancreatic ducts in the cells that produce enzymes.  
• Sarcomas - tumors that form in the connective tissue that bonds 
together the pancreatic cells. This is very rare.  
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• Ampullary Cancers - cancer that develops in the ampulla of 
Vater (where pancreatic ducts and bile ducts merge). 
  
Pancreatic Cancer: Risk Factors (AB Lowenfels et al., 2002) 
 Age 
 Increased Body Mass Index (BMI) 
 Smoking 
 Diabetes 
 Chronic Inflammation 
 
Pancreatic Cancer: Symptoms (R Freelove et al .,2006) 
 Jaundice 
  Weight Loss 
  Pain in the abdomen and back  
 Steatorrhoea 
 Glucose Intolerance 
 
Pancreatic Cancer: Detection and Diagnosis 
 Preoperative imaging done with CT scan or ultrasound to 
determine location and size of the tumor  
 ERCP and biopsy may be used for further evaluation of the 
tumor  
 
Pancreatic Cancer: Treatment 
 Chemotherapy  
 Surgical Resection 
 Radiation Therapy 
 Palliative Care and Pain Management 
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Prostate Cancer: Introduction 
Prostate cancer is a common cancer affecting the lives of millions 
of men worldwide. In 2010, the American Cancer Society estimates 
217,730 new cases will be diagnosed and 32,050 men will die of the 
disease in the United States. 
 
Prostate Cancer: Risk Factors (Cox B et al ., 2006) 
 Age  
 Family History of Prostate Cancer  
 Race  
 Dietary Factors  
 
Prostate Cancer: Symptoms 
 Inability to urinate  
 Discontinuous or weak urine flow  
 Difficulty in starting or stopping urine flow  
 Frequent urination, especially at night  
 Blood in urine  
 Pain or burning with urination  
 Continuous back, pelvis, or upper thigh pain  
 
Prostate Cancer: Detection and Diagnosis 
 Digital Rectal Examinations 
 
 Prostate Specific Antigen (PSA) Test 
 
 Biopsy 
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Prostate Cancer: Treatment 
 
 Radical prostatectomy  
 Transurethral resection of the prostate (TURP)  
 External beam radiation  
 Internal radiation: brachytherapy  
 Hormone therapy  
 Removal of the testicles (orchiectomy)  
 Chemotherapy 
 
Introduction to Skin Cancer 
Malignancies of the skin are the most commonly diagnosed 
cancer type worldwide. The foremost cause of skin cancer remains UV 
radiation from sunlight. Skin cancer may be classified as either non-
melanoma skin cancer (cancer types include squamous cell carcinoma 
and basal cell carcinoma) or melanoma (Miller AJ et al., 2006). 
 
Types of Skin Cancer (Holcomb SS et al., 2006) 
Skin cancer may be divided into two types: non-melanoma and 
melanoma. 
 
 
 
Nonmelanoma Skin Cancer 
          There are two major sub-types of non-melanoma skin cancer: 
 Basal Cell Carcinoma- The most commonly diagnosed skin 
cancer   
 Squamous Cell Carcinoma- Appears on body parts that 
experience increased levels of sun exposure such as the face, lips 
and back.  
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Melanoma 
          Melanoma is a cancerous growth of melanocytes and most 
frequently develops in the skin. There are several types of melanoma 
that can be categorized based on their appearance, either with the 
naked eye or microscopically. 
 Superficial spreading  
 Nodular type lesions 
 Acral lentiginous lesions 
 Lentigo maligna melanoma 
 
Skin Cancer: Risk Factors  
 Ultraviolet Radiation  
 Skin Color  
 Sun Sensitivity  
 Immunosuppression  
 Prior Diagnosis  
 Family History  
 Radiation Therapy  
 Chemical Exposure   
 
Skin Cancer: Symptoms and Detection (Rager EL et al .,2005) 
 Asymmetry: melanomas tend to be asymmetrical while benign 
lesions are more rounded and symmetric.  
 Borders: Benign lesions are usually regular and flush with the 
skin while melanomas may have irregular and/or raised 
borders.  
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 Color: Melanomas may be tan, black or brown and often include 
regions of red, white and blue.  
 Diameter: In general, melanomas are larger than 6 mm in 
diameter.  
 Evolution: Changes in physical appearance of melanocytic 
growths are often observed over time and skin marking should 
be monitored for changes.  
 
Skin Cancer: Treatment (Rubin AI et al., 2005) 
• Surgical Treatment 
Excision of a skin cancer lesion is a frequent treatment 
option.  Excision may be curative for diseases that are in stages I 
or II (localized). 
 
Non-surgical Treatment 
Examples of nonsurgical treatment options include: 
 
 Radiotherapy  
  Photodynamic Therapy   
 Topical Drug Treatments 
  Biological Treatments  
 Specific Inhibitors 
 
Gastric Cancer: Introduction (Hohenberger P et al., 2003) 
Gastric or stomach cancer is relatively rare in the United States 
and other developed countries. According to the American Cancer 
Society, it is estimated that in 2010, 21,000 cases of gastric cancer will be 
diagnosed.  
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Gastric Cancer: Types 
 Gastric adenocarcinoma  
 Gastrointestinal Stromal Tumor (GIST)  
 Gastrointestinal Leiomyosarcoma  
 Gastrointestinal Carcinoid  
 Gastrointestinal lymphoma  
 
Gastric Cancer: Risk Factors (Rocco A et al., 2007) 
 Helicobacter pylori infection  
 Diet  
 Gender  
 Age  
 Ethnicity  
 Geography   
 
Gastric Cancer: Symptoms (Layke JC et al., 2004) 
 Indigestion, stomach discomfort, or heartburn  
 Nausea or loss of appetite  
 Feeling tired  
 
Late-stage gastric cancers are associated with the following symptoms: 
 Blood in the stool or stools that are black in color  
 A bloated feeling after eating, even when eating a small amount  
 
Gastric Cancer: Treatment 
 Surgery  
 Radiation Therapy  
 Chemotherapy  
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Cancer Prevention: 
 
Antioxidants 
The possible role of antioxidants in the prevention and treatment 
of a variety of medical conditions has been very highly publicized.  For 
some diseases, anti-oxidants may well play an important role 
 
Sources and Uses of Antioxidants 
There are many good sources of antioxidants including green 
tea, berries, tomatoes and soy. Antioxidants can be found in many 
fruits and vegetables because plants produce antioxidants to help 
protect themselves from free radicals created by radiation from the sun. 
 
Detection and Diagnosis (Graham DYet al., 2010) 
 
Biopsy 
A biopsy is the removal of either a portion of a lesion (incisional) 
or the entire lesion (excisional).  The tissue is then sent to a lab where a 
pathologist will diagnose the sample. There are two categories of 
biopsies. 
 
Types of Biopsies 
There are several different types of biopsy.  The type used 
depends on the goal of the biopsy (i.e. remove the entire lesion or 
obtain a small sample), the cancer type and the location of the cancer. 
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1. Incisional 
An incisional biopsy removes only a portion of a suspected 
tumor. This technique is used when a lesion is too large to remove 
entirely or when the location of the tumor would result in unacceptable 
amounts of scarring.  
 
2. Excisional 
An excisional biopsy removes the entire tumor and some 
surrounding tissue. If a diagnosis of cancer results, the biopsy will have 
removed the entire tumor. These biopsies usually produce a scar. 
There are various different techniques used for excisional and incisional 
biopsies. Punch, Shave, and Needle. 
 
 Punch 
A punch biopsy is used to collect a deep sample of skin and is 
usually used for large lesions or lesions on the palm, sole, finger/toe, 
face, and ear.  
 
 Shave 
A shave biopsy removes the epidermis and a small portion of the 
dermis. This technique uses a surgical blade or razor to shave off a 
portion of the skin.  
 
 Needle 
A needle biopsy is rarely used to obtain skin tissue; it is usually 
used to remove a sample from internal organs, lymph nodes, or deep 
skin areas. These techniques involve the use of a small, hollow needle 
and are sometimes aided by an imaging technique such as x-ray.  There 
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are two types of needle biopsy, fine needle aspiration (FNA) and core 
needle biopsy (CNB). 
 
Bronchoscopy 
Bronchoscopy is the use of a flexible or rigid tube to examine the 
airways.  Bronchoscopy is used to detect and diagnose lung cancer.  It 
is also used to remove airway blockages (i.e. food), to treat bleeding, to 
deliver radiation to cancerous areas (brachytherapy) and to take small 
tissue samples (biopsies).   
 
Cancer Antigen 125 (CA 125) Test 
CA 125 (cancer antigen 125 or carbohydrate antigen 125) is a 
glycoprotein that is produced by the uterus, cervix, fallopian tubes, and 
the lining of the chest and abdomen.  
 
Colonoscopy 
Colonoscopy is a diagnostic technique that allows physicians to 
visually inspect the interior lining of the colon. A colonoscopy allows a 
doctor to examine the inside of the entire colon for abnormalities, 
including; intestinal inflammation, ulceration, bleeding, diverticulitis, 
colitis, colon polyps, and tumors.  
    
Pap test 
A pap test can detect pre-cancerous and cancerous cells in the 
vagina and cervix. The cervix is the lower part of the uterus that 
connects the vagina with the main part of the uterus. In a Pap test a 
small sample of cells is removed from the cervix with a brush or 
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spatula.  The image below shows the process.  The procedure is not 
painful as only the surface of the cervix is touched.  The cells are then 
smeared onto a slide and examined under a microscope.  A Pap test can 
identify abnormal cells and detect changes before cancer has fully 
developed. 
 
Breast Exam 
Breast exams are the first step in early detection of breast cancer. 
The American Cancer Society recommends: 
 women over 20 should do a monthly breast self exam  
 women in 20's and 30's should have a clinical breast exam every 
3 years  
 women over 40 should have a clinical breast exam yearly  
 
 
Self Breast Exam 
A self breast exam involves looking at and feeling your breasts to 
detect any abnormalities or changes.  
 
Clinical Breast Exam 
Clinical breast exams should be done by a physician, nurse 
practitioner, or other specially trained medical professional who is well 
trained in the technique during a routine medical exam. 
 
Mammography 
It is recommended that women age 40 and older have regular 
mammograms. Screening is important because the earlier cancer is 
detected the better the chances are for successful treatment and 
survival. When detection occurs before any spread, the five-year 
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survival rate is 97%. After spread to the local lymph nodes, it is 76%. 
After metastasis to other organs, the five-year survival rate is 20%. The 
image showed is a labeled representation of a mammography machine. 
 
Ultrasound Imaging 
Ultrasound, also called ultrasound scanning or sonography is an 
imaging method that uses sound waves to create an image of a part of 
the body. Unlike mammograms, which use radiation (x-rays), 
ultrasounds expose the body region of interest to high-frequency sound 
waves.  
 
The computer collects the echoes and creates an image on the 
screen. In creating the final image, the computer analyzes several 
characteristics of the returned sound waves: 
 
 Amplitude: strength of the signal  
 Frequency: the number of waves received per second  
 Time Delay: the time it takes for the signal to return from the 
targeted region to the transducer. 
  
Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) is a non-invasive way to 
view organs, tissues, bones, and other structures inside the body. It 
uses strong magnetic fields and radio waves to produce internal images 
of the body. An MRI machine is a large, cylinder shaped machine that 
contains a very strong donut-shaped magnet. Magnets are commonly 
measured using gauss and an MRI magnet can be up to 20,000 gauss 
(common refrigerator magnets are around 10 gauss).  
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Fine Needle Aspiration (FNA) 
A FNA is a type of biopsy.  In a biopsy a small sample of tissue is 
removed for examination by a pathologist.  The doctors look at the 
samples under a microscope and may stain the cells with different dyes 
to help them distinguish between normal and abnormal cells.   
 
Analysis 
            Samples are sent to a pathologist specially trained in cytology 
(cellular abnormalities) to be processed and interpreted. The samples 
are placed on glass slides and stains are used to reveal the details of the 
cells. The diagnosis will generally come back as one of five options: 
 
 Benign - the mass is not of much concern and will not cause any 
significant problems as long as it remains unchanged.  
 Atypically indeterminate - a diagnosis cannot be obtained from the 
sample. Other tests are needed to determine the nature of the 
lesion.  
 Suspicious/probably malignant - not a diagnosis of cancer. This 
lesion should be biopsied with a more complete method to 
determine whether a malignancy (cancer) is present.  
 Malignant - a diagnosis of cancer; should be biopsied and tested 
for exact tumor makeup to prepare for treatment.  
 
Core Needle Biopsy (CNB) 
Biopsies are samples of tissue that are removed for closer 
examination. 
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Analysis 
            A core biopsy sample is studied differently than a FNA sample. 
The larger size of the sample allows the pathologist to look at the way 
groups of cells are organized instead of looking at individual cells. In 
CNB a trained pathologist looks for changes associated with a variety 
of diseases. Because cancer cells are dividing in an abnormal fashion, 
they make the tissue around them appear disorganized.  
 
Cancer Treatments 
        The major types of treatment and their objective are described 
briefly below. 
¾ Surgery: Often the first line of treatment for many solid tumors. 
In cases in which the cancer is detected at an early stage, surgery 
may be sufficient to cure the patient by removing all cancerous 
cells. Benign growths may also be removed by surgery. 
¾ Radiation: May be used in conjunction with surgery and/or 
drug treatments. The goal of radiation is to kill the cancer cells 
directly by damaging them with high energy beams.  
¾ Chemotherapy: A term used for a wide array of drugs used to 
kill cancer cells. Chemotherapy drugs work by damaging the 
dividing cancer cells and preventing further reproduction.  
¾ Hormonal Treatments: These drugs are designed to prevent 
cancer cell growth by preventing the cells from receiving signals 
necessary for their continued growth and division.  
¾ Targeted Therapy: This class of drugs is relatively new in the 
treatment of cancer. They work by targeting specific proteins and 
processes that are limited primarily to cancer cells or that are 
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much more prevalent in cancer cells. Inhibition of these 
processes prevents cancer cell growth and division. 
¾ Antibodies: This treatment involves the use of antibodies to 
target cancer cells. While antibodies are naturally occurring 
proteins in our bodies, the antibodies used in the treatment of 
cancer have been manufactured for use as drugs.  
¾ Biological Response Modifiers: These treatments involve the 
use of naturally occurring, normal proteins that stimulate the 
body's own defenses against cancer.  
¾ Vaccines: The purpose of cancer vaccines is to stimulate the 
body's defenses against cancer. Vaccines usually contain proteins 
found on or produced by cancer cells.  
¾ Complementary and Alternative Medicines: These treatment 
methods are not practiced by conventional western medicine. 
They can include herbal, animal derived, and mind-body 
approaches to treating cancer. 
 
Biological Response Modifiers (BRM) 
Biological response modifiers are compounds that are used to 
treat cancer by altering or augmenting naturally occurring processes 
within the body. Immunotherapy makes use of BRMs to enhance the 
activity of the immune system to increase the body's natural defense 
mechanisms against cancer. 
 
The cytokines most frequently used to treat cancer are: 
 Interleukin-2 (IL-2)  
 Alpha Interferon (IFN) 
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Bone Marrow Transplant (BMT) 
Bone marrow transplant is used to treat several types of cancer 
and is commonly used for leukemias, lymphomas and other blood cell 
cancers.   BMT may also be used to treat patients with solid tumors.  
 
Chemotherapy (Lippincott’s et al., 1999) 
The term chemotherapy or chemo refers to a wide range of drugs 
used to treat cancer. These drugs usually work by killing dividing cells. 
Since cancer cells have lost many of the regulatory functions present in 
normal cells, they will continue to attempt to divide when other cells 
do not.  
 Antimetabolite: Drugs that interfere with the formation of key 
bio-molecules within the cell including nucleotides, the building 
blocks of DNA. These drugs ultimately interfere with DNA 
replication and therefore cell division.  
 Genotoxic Drugs: Drugs that damage DNA. By causing DNA 
damage, these agents interfere with DNA replication, and cell 
division. 
 Spindle Inhibitors: These agents prevent proper cell division by 
interfering with the cytoskeletal components that enable one cell 
to divide into two. 
 
Antimetabolites 
 
Many of the antimetabolites used in the treatment of cancer 
interfere with the production of the nucleic acids, RNA and DNA.If 
new DNA cannot be made, cells are unable to divide. There are several 
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different cellular targets for antimetabolites. Some common classes of 
antimetabolites are: 
 
• Folate Antagonists  
• Purine Antagonists  
• Pyrimidine Antagonists  
 
Folate Antagonists 
 
Folate antagonists, also known as antifolates, inhibit dihydrofolate 
reductase (DHFR), an enzyme involved in the formation of nucleotides. 
When this enzyme is blocked, nucleotides are not formed, which 
disrupts DNA replication and cell division.  
 Methotrexate 
 Pemetrexed (Alimta®) 
 
Purine Antagonists 
 
The purines (adenine and guanine) are chemicals used to build 
the nucleotides of DNA and RNA. The other classes of base, the 
pyrimidines, are represented in DNA by thymine and cytosine and in 
RNA by cytosine and uracil.The purine antagonists function by 
inhibiting DNA synthesis in two different ways:  
 
 6-Mercaptopurine  
 Dacarbazine  
 Fludarabine  
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Pyrimidine Antagonists 
    The pyrimidine antagonists act to block the synthesis of 
pyrimidine containing nucleotides (C and T in DNA; C and U in RNA). 
The drugs used to block the construction of these nucleotides have 
structures that are similar to the natural compound. Some pyrimidine 
antagonists used in cancer therapy are: 
 5-fluorouracil  
 Arabinosylcytosine  
 Capecitabine  
 Gemcitabine  
 Decitabine  
 
Genotoxic Drugs 
Genotoxic drugs are chemotherapy agents that affect nucleic 
acids and alter their function. These drugs may directly bind to DNA or 
they may indirectly lead to DNA damage by affecting enzymes 
involved in DNA replication. 
 
The genotoxic chemotherapy treatments include: 
 
 Alkylating agents: The first class of chemotherapy agents used. 
These drugs modify the bases of DNA, interfering with DNA 
replication and transcription and leading to mutations. 
 Intercalating agents: These drugs wedge themselves into the 
spaces between the nucleotides in the DNA double helix. They 
interfere with transcription, replication and induce mutations.  
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 Enzyme inhibitors: These drugs inhibit key enzymes, such as 
topoisomerases, involved in DNA replication inducing DNA 
damage. 
 
Cryotherapy (Cryoablation) 
Cryotherapy or cryoablation (Cryo is from the Greek for frost or 
extreme cold. Ablation refers to removal or elimination.)  is the use of 
extreme cold to kill tumor cells.   A probe containing an extremely cold 
fluid is placed inside/on the area to be treated and the tumor (or 
abnormal growth) is frozen.  Cryotherapy can be performed during a 
open (fully invasive) surgery or the probes can be inserted through the 
skin in a minimally invasive procedure. 
 
Radiofrequency Ablation (RFA) 
It has been known for a long time that normal cellular functions 
will stop if the temperature is raised to 42°C/108°F, and that large-scale 
cell death--necrosis--will occur at temperatures above 46°C/115°F. 
Killing cells with heat presents a possible method of cancer treatment; 
obviously, measures must be taken to minimize the heating of 
surrounding healthy cells. 
 
Surgery for Cancer 
Surgery is frequently used to remove cancerous growths or 
obtain small samples of tissue for examination. For several types of 
cancer, surgical removal of a tumor may be sufficient to cure the 
patient. The likelihood of a surgical cure is dependent on the size, 
location, and stage of the disease. When removing a tumor the surgeon 
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will try to remove as much of the tumor as possible. The tissue 
removed from the patient will often be examined by a pathologist for 
signs of tumor cells near the edge of the incision.  
 
Hormonal Cancer Treatments 
The hormonal treatments described on the following pages all work 
by interfering with hormonal signals but they may attack different 
parts of the pathways involved. The types of hormonal antagonists 
(and specific drugs) discussed include: 
 
 Selective Estrogen Receptor Modulators (SERMs) 
 Aromatase Inhibitors 
 Receptor Down-regulators 
 Selective Androgen Receptor Modulators (SARMs) 
 
Targeted Therapy 
The development of targeted therapy represents an exciting new 
approach to cancer treatment. A small number of these drugs have 
already been FDA approved and several others are currently in 
clinical trials. 
 
 Kinases are enzymes that add phosphate groups onto proteins. 
Because they control many cellular processes, abnormal activity 
can result in the development of cancer.  
 Angiogenesis Inhibitors, Angiogenesis, the development of 
blood vessels, is critical to the growth of almost all types of 
cancer.  
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 Proteasome Inhibitors, Proteasomes are responsible for the 
destruction of proteins. Inhibition of proteasome activity be used 
to treat some types of cancer.  
 
Tumor Vaccines 
The aim of tumor vaccines is to stimulate the body's immune 
system in the fight to recognize and eliminate cancer cells. There are 
many strategies in immunotherapy; some strategies are considered 
'passive' while others are 'active'. 
 
• Passive immunotherapy involves giving antibodies or mature T 
cells to the patient to attack the cancer cells. This type of therapy 
does not induce permanent change in the patient's own T cells, 
but may be effective in a variety of cancers including leukemia 
and breast cancer.  
• Active immunotherapy strategies include tumor vaccines, 
because they directly stimulate the patient's own immune cells 
to have a long-lasting response against the cancer. 
 
There are several broad categories of tumor vaccine strategies: 
 Whole cell vaccine 
 Antigen therapy vaccines 
 Antigen-presenting cell vaccines 
 Non-specific therapy and cytokine therapy 
 
Managing Side Effects 
Cancer and cancer treatment can cause many side effects; some 
are easily controlled and others require specialized care. 
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 Anemia 
 Anxiety - ASCO curriculum 
 Appetite Loss 
 Bleeding and Clotting Problems 
 Blocked Intestine or Gastrointestinal Obstruction - ASCO
curriculum 
 Constipation 
 Depression - ASCO curriculum 
 Diarrhoea - ASCO curriculum 
 Difficulty Swallowing or Dysphagia 
 Dry Mouth or Xerostomia 
 Edema or Fluid Retention 
 Fatigue - ASCO curriculum 
 Hair Loss or Alopecia 
 Mouth Sores or Mucositis - ASCO curriculum 
 Nausea and Vomiting 
 Pain - ASCO curriculum 
 Sexual Dysfunction - ASCO curriculum 
 Skin Reactions to Targeted Therapies 
 Taste Changes 
 Thrombocytopenia 
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Cancer Drug Resistance 
One of the main causes of failure in the treatment of cancer is the 
development of drug resistance by the cancer cells. It is possible that 
more than one of these resistance mechanisms can occur in any given 
case. 
  
 The Selection of Resistant Cells   
 Gene Amplification  
 Multiple Drug Resistance  
 Blood-Brain Barrier  
 Changes in Target Molecules  
 
 
Cancer Treatment Tables 
Cancer is treated with a wide variety of drugs. This section contains 
the following tables: 
 
 Chemotherapy Drugs  
 Hormonal Drugs  
 Biological Drugs  
 Antibody-based Treatments  
 Targeted Therapies  
 Complementary and Alternative Medicine (CAM)  
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Table 3: Chemotherapy Drug Table 
 
Generic Name Brand Name 
Type of 
Chemotherapy 
Arabinosylcytosine 
(ARA-C), 
Cytarabine 
Cytosar-U® Antimetabolite 
Bleomycin Blenoxane® Other 
Busulfan Myleran® Genotoxic Agent 
Capecitabine Xeloda® Antimetabolite 
Carboplatin Paraplatin® Genotoxic Agent 
Carmustine Bicnu®, Gliadel® Genotoxic Agent 
Chlorambucil Leukeran® Genotoxic Agent 
Cisplatin 
Platinol®, IntraDose®(Cisplatin; 
Collagen; Epinephrine) 
Genotoxic Agent 
Cyclophosphamide 
Cytoxan®, Cytoxan®IV, Neosar®, 
Procytox® 
Genotoxic Agent 
Dacarbazine DTIC-Dome® 
Genotoxic Agent 
or 
Antimetabolite 
Daunorubicin Cerubidine Genotoxic Agent 
Docetaxel Taxotere® Spindle Inhibitor 
Doxorubicin 
Adriamycin®, Rubex®, Doxil®, 
Caelyx®, Myocet™ 
Genotoxic Agent 
Epirubicin Ellence® Genotoxic Agent 
Etoposide 
Etopophos®, Vepesid®,  Toposar®, 
VP-16® 
Genotoxic Agent 
Fludarabine Fludara® Antimetabolite 
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Table 4: Hormonal, Biological and Antibody-based Treatment Tables 
 
Generic 
Name 
Brand 
Name 
Type of Hormonal Treatment 
Anastrozole Arimidex® Aromatase Inhibitor 
Bicalutamide Casodex® Exemestane 
Flutamide Eulexin® Specific Androgen Receptor Modulator(SARM) 
Fulvestrant Faslodex® Estrogen Receptor Down-Regulator 
Megestrol Megace® Additional Hormonal Treatments 
Tamoxifen Nolvadex® Selective Estrogen Receptor Modulator (SERM) 
  
Table 5: Biological Treatments 
 
Generic Name Brand Name Type of Drug 
Aldesleukin, Interleukin-2  Proleukin® BRM 
Alpha Interferon Intron®, Roferon®-A BRM 
Imiquimod Aldara® BRM 
Lenalidomide Revlimid® BRM 
 
Table 6: Antibody Treatments 
 
Generic Name Brand Name Type of Drug 
Alemtuzumab Campath® Antibody 
Bevacizumab Avastin® Antibody 
Gemtuzumab Mylotarg® Antibody 
Ibritumomab Zevalin® Antibody 
Trastuzumab Herceptin® Antibody 
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                               Table 7: Targeted Therapies Treatment Table 
 
Generic Name Brand Name Mechanism of Action 
Asparaginase Elspar® Enzyme Activator 
Bevacizumab Avastin® Angiogenesis Inhibitors 
Bexarotene Targretin® Drug that affects a Molecular Receptor 
Gefitinib Iressa® Kinase Inhibitor 
Imatinib 
Mesylate 
Gleevec®, 
Glivec® 
Kinase Inhibitor 
 
 
RADIATION THERAPY  
 
Ionising radiation used in radiotherapy causes damage to all 
living cells, both normal and malignant. The side effects result from 
damage to cells. The cells that divide rapidly such as skin, bone 
marrow and the gastrointestinal mucosa are more quickly affected. 
Acute radiation reactions occur between 10-14 days from the start of 
radiotherapy and continue to increase in severity until the completion 
of treatment. 
 
Goals of Radiation Therapy 
There are two possible goals of radiotherapy  
1. Curative radiotherapy 
2. Palliative therapy  
The former is used for the purpose of curing the patient and the 
patient has to engender a small risk of significant side effects. E.g. In 
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treatment of early stage of Hodgkin’s disease, a small risk of myelitis is 
encountered. The latter is to ameliorate a specific symptom such as 
pain, obstruction or bleeding. E.g. to relieve pain from metastasis of a 
distant primary tumor to a bone, one chooses a dose and technique of 
radiotherapy sufficient to achieve relief of pain but not enough to a risk 
of osteo-radio-necrosis. 
   
Types of Cancer Treated by Radiation  
 skin and lip  
 head and neck  
 breast  
 cervical and endometrium  
 Oral cancers 
 prostate  
 Hodgkin's disease and local extranodal lymphoma  
 seminoma of testis and dysgerminoma of ovary  
 medulloblastoma, pineal germinoma,and ependymoma  
 retinoblastoma  
 choroidal melanoma  
 
Types of Radiation Therapy 
Radiation can harm both cancerous and normal tissues, the 
treatment is based on the fact that fast growing cells, such as those 
found in tumors, are more sensitive to radiation damage. The 
radiotherapy technique used depends on the type, extent and location 
of the cancer, and the goal of treatment. 
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Internal radiation called brachytherapy is the process of implanting 
radioactive material onto or near the tumor or placing radioactive 
sources into the body. It can be temporary or permanent. Depending on 
the location of the implant the treatment may be handled as either an 
in- or out-patient procedure.  
   
 
 
 
 
 
 
 
Figure 2: Internal and external radiation  
 
External radiation therapy utilizes a machine to deliver radiation to the 
tumor. This therapy is primarily an outpatient treatment. Most 
protocols last approximately 4-7 weeks with treatments given 5 days 
per week. Both internal and external therapies act to destroy the ability 
of the cancer cells to reproduce. There are several different types of 
radiation that may be utilized 
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Administration of Radiation Therapy 
There are several different ways to administer radiation. Some of 
the more common are listed below. Many new procedures are currently 
under investigation. 
 
Internal 
 Seed implants  
This method is most often used to treat prostate cancer. 
Radioactive seeds are implanted and placed directly on the 
cancer mass. The seeds are smaller than a grain of rice. Up to 150 
seeds may be implanted.  
 Brachytherapy 
This method is most often used as a local treatment for early 
stage carcinomas. Sealed radioactive sources are used to deliver 
radiation to the tumor from a short distance. The two radioactive 
sources used are 103Pd and 125I.  
 
External 
 External Beam Radiation Therapy This method uses large machines 
to produce high and low energy X-ray beams. The amount of 
radiation required is dependent upon the type of cancer. For 
example, the level of radiation necessary to destroy a skin 
carcinoma is less than the amount needed to treat a cancer that is 
located deep within the body.  
 3-D Conformal Therapy and Intensity Modulated Radiation Therapy 
(IMRT)  
This method, which is newer and more precise than external 
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beam, uses computer imaging to calculate the most efficient dose 
and combination of radiation treatments.  
 
MECHANISM OF ACTION 
Ionizing radiation acts directly and indirectly on viable cells of 
neoplasm as well as on normal cells near by the lesion (Perez et al., 
2007). 
One-Third (1/3) of the biological effects of irradiation is by direct 
damage to cells. It is caused by high energy photons or electrons hitting 
the cell and changes are brought about within 10-10 seconds. RNA and 
DNA damage are produced by breaking the relatively weak bonds 
between the nucleic acids. The volume of viable cells which absorb 
radiation energy is inactivated. As a result of irradiation, DNA damage 
occurs in normal somatic cells, in reproductive cells and in tumor cells, 
resulting in radiation induced malignancy, radiation induced 
congenital anomaly and radiation induced tumor cell apoptosis leading 
to cell death, respectively.  
Two-Third (2/3) of the biological effects of radiation is by the 
indirect damage to cells. Photons are absorbed by water and cause 
radiolysis. Water being the predominant molecule in biological system 
(75%) which interacts and produces changes.  
          Ionizing 
H2 O                     H2O + + e- dissociates at once H+ + OH+ 
          Radiation 
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H2O + e-  - H2O -  Dissociates at once H- + OH- 
  
H+ + H  -  H2  
OH+ + OH  -  H2O2  
 
Free radicals H+, H-, OH+, OH- are unstable. Being highly 
reactive, they combine with one another and break protein linkages in 
DNA. These ionizing radiations, which arrest cell division or cause cell 
death, are used in radiation therapy.  
DOSE 
Radiation dose selection is a complex issue. Determination of 
correct number of fraction of radiation per day, the correct dose per 
fraction, the proposed total dose of irradiation depends on two factors. 
Factor-1 is the tumor control within radiotherapy field as function of 
the dose administered. Factor-2 is the normal tissue tolerance, a 
balancing act between a sufficient dose of radiation to control tumor 
and not so much dose to cause ill effects. 
The amount of radiation used in radiation therapy is measured 
in gray (Gy), and varies depending on the type and stage of cancer 
being treated. For curative cases, the typical dose for a solid epithelial 
tumor ranges from 60 to 80 Gy, while lymphoma tumors are treated 
with 20 to 40 Gy. 
FRACTIONATION 
The total dose is fractionated (spread out over time) for several 
important reasons. Fractionation allows normal cells time to recover, 
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while tumor cells are generally less efficient in repair between fractions 
(Parsons et al., 1988). Fractionation also allows tumor cells that were in 
a relatively radio-resistant phase of the cell cycle during one treatment 
to cycle into a sensitive phase of the cycle before the next fraction is 
given. Similarly, tumor cells that were chronically or acutely hypoxic 
(and therefore more radio resistant) may reoxygenate between 
fractions, improving the tumor cell kill.  
 
Benefits of Radiation Therapy 
 Destroys quickly dividing cells at the margins of tumors. Surgery 
may miss these cells leading to recurrence of disease.  
 Can successfully eradicate growth without permanently 
damaging the adjacent normal tissue. If these tumors can be 
treated early before metastasis, there is a very high rate of 
curability.  
 In conjunction with other treatments, may cure tumors that are 
not responsive to any single agent.  
 Radioactive seed implants can deliver high doses of radiation 
directly to the tumor sparing nearby healthy cells. Has less 
severe side effects than external radiation therapy.  
 Preoperative radiation therapy can kill tumor cells at margins of 
the tumor site. It can keep the cancer under control and prevent 
metastases, and also convert technically inoperable tumors into 
operable ones.  
 Postoperative radiation therapy can destroy cancer cells still 
present around the margins after a tumor has been surgically 
removed.  
 
 
 
Introduction  
 
51 
 
Radiation Side Effects 
Radiation treatments use high energy waves to damage and kill 
cancer cells. Because the radiation can affect cells other than cancer 
cells, side effects may occur. The side effects that any given patient has 
depend on the type and amount of radiation used and the area being 
treated. 
 
Possible side effects include: 
 Fatigue (in part due to energy expended in replacing normal 
cells killed in the process)  
 Skin irritation, redness, lesions, peeling  
 Hair loss  
 Loss of taste  
 Erectile dysfunction  
 Decreased blood count (may be monitored by the clinician 
overseeing the treatment)  
 Increased susceptibility to infection  
 Difficulty swallowing and decreased appetite  
 Oral mucositis (cells of the mouth rapidly dividing)  
 
Types of Skin Reactions Occur  
Radiation-induced skin reactions may progress from erythema 
(redness), to desquamation (shedding of outer skin layers), and 
sometimes to ulceration. During the first week or two of radiation 
treatment, subjects may notice a faint redness and your skin may 
become itchy or tender. After three to four weeks, skin may become dry 
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and peel or you may notice moist areas. Later effects of radiation may 
include darkening or thinning of the skin. 
 
The following are some common reactions that can occur on radiated 
skin: 
 Rash, redness, sunburned-like appearance 
 Itching (pruritus), flaking, scaling 
 Tenderness, discomfort, pain, burning 
 Dryness, peeling 
 Blisters, sores, ulcers 
 Moist (weeping) areas, oozing 
 Swollen, puffiness 
 Infection 
 Increased sensitivity to sunlight 
 
RISK FACTORS FOR SKIN REACTIONS  
Radiosensitivity of tissues varies between individuals and 
between the various skin structures. A number of factors can affect the 
potential for skin reactions and include the total dose of radiation 
given, the location of the area treated and the volume of tissue 
irradiated. Previous exposure to ultraviolet radiation and increasing 
age causes the skin to be more fragile and sensitive, along with medical 
conditions such as diabetes, and immune compromised status and 
previous surgery. Patients with a poor nutritional status, those who 
smoke tobacco and on steroid therapy are all in the high risk category 
(Turesson et al., 1996) (Harper et al., 2004).  
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CHEMOTHERAPY AND RADIATION  
Studies have found instances when chemotherapy in association 
with radiation produces skin changes, and can be classified as acute 
responding (occurring weeks to months after irradiation and late 
responding (occurring months to years) after treatment. The 
simultaneous administration of chemotherapy and radiotherapy can 
produce an intense skin reaction e.g.  
 Doxorubicin may produce skin erythema, vesiculation, 
desquamation or hyperpigmentation.  
 Methotrexate may cause erythema and ulceration.  
 
TOLERABILITY OF RADIATION THERAPY 
Full-dose radiation is usually given only once to a particular part of 
the body. The normal tissues can safely tolerate a limited amount of 
radiation. Radiation oncologist picks the right dose of radiation to 
accomplish 2 things: 
 To reach the maximum therapeutic dose — the amount that's 
likely to destroy cancer cells  
 To avoid or minimize side effects to the normal tissue 
 
After radiation is over, the normal tissues heal and get back to 
normal. If cancer returns to the same breast area, depending on the 
radiation dose you already received, you may or may not be able to 
receive a limited amount of additional radiation treatment in that same 
area. 
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SEQUENCES OF RADIATION THERAPY 
The sequence and timing of radiation treatment depends on your 
individual situation. Radiation may be given immediately after surgery 
or after other forms of treatment. Here are some examples of various 
treatment sequences that involve radiation: 
 
• surgery → radiation → possible hormonal therapy  
• surgery → chemotherapy → radiation → possible hormonal 
therapy  
• chemotherapy, targeted therapy, or hormonal therapy → surgery 
→ radiation → possible hormonal therapy 
 
RADIODERMATITIS: 
Radiodermatitis, also known as radiation dermatitis or radiation 
skin reaction, is caused by the changes cells undergo in the basal layer 
of the epidermis and the dermis (Wickline, 2004).Up to an estimated 
95% of patients receiving radiation therapy will experience some 
degree of skin reaction, which may include erythema, dry 
desquamation, and moist desquamation (De Conno, Ventafridda, & 
Saita, 1991; King, Nail, Kreamer, Strohl, Johnson, 1985; Porock & 
Kristjanson, 1999). 
 
Approximately 95% of radiation oncology patients will 
experience radiodermatitis and 87% will experience moderate to severe 
radiodermatitis during or after their therapy (McQuestion, 2006; Fisher 
J et al., 2000). 
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PATHOPHYSIOLOGY 
The skin is the largest organ of the body and is composed of two 
layers, the epidermis and the dermis. The most superficial layer, the 
epidermis, is made up of a thin layer (< 2 mm) of keratinized squamous 
cells that serve as a protective barrier against pathogens and prevent 
water loss from the body (McQuestion, 2006). The dermal layer is 
slightly thicker (1-3 mm) and contains blood vessels that nourish the 
skin and assist with thermoregulation (Harper, Franklin, Jenrette, & 
Aguero, 2004). The dermis also contains nerves that are responsible for 
sensation, glands that are involved in immune function, and hair 
follicles (McQuestion, 2006). The skin is continually renewing itself. 
New skin cells proliferate and mature at the dermal layer and migrate 
to the epidermis over a period of two to three weeks. 
           The microscopic image of a radio dermatitis lesion given can 
easily distinguish the thick keratin layer below the epidermis, which 
would certainly show as an area of increased density on a 
mammogram, there is no evidence of any malignant cell activity.  
 
Radiodermatitis may be acute or chronic and exists on a 
continuum of erythema, epilation, desquamation, ulceration, or 
necrosis. Acute skin changes occur within 90 days of initiating therapy 
as a result of cytokine-mediated inflammation and DNA damage 
(Hymes, Strom, and Fife, 2006; Muller, Khan, Port, Abend, Molls, 
Ring, & Meineke, 2006). 
 
• Erythema and swelling may begin within hours or days of 
initiating radiation therapy due to the release of cytokines that 
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cause capillary dilation, leukocyte infiltration, and localized 
swelling (Hymes, Strom, and Fife, 2006; McQuestion, 2006). 
• Dryness and epilation may occur within days to weeks due to 
damage of sebaceous glands and hair follicles in the dermal layer 
(McQuestion, 2006). 
• Dry desquamation, characterized by dryness, scaling, and 
pruritus, typically can occur after the third week or after a 
cumulative dose of 30 Gy due to destruction of regenerative 
basal cells (Richardson, Smith, McIntyre, Thomas, & 
Pilkington, 2005). 
• Dry desquamation typically resolves within one to two weeks of 
therapy (McQuestion, 2006). 
• Moist desquamation, evidenced by red, exposed dermis and 
serous oozing, occurs after four to five weeks of therapy or with 
45 to 60 Gy cumulative dose as the basal cells are further 
depleted (Richardson et al., 2005). Acute radiodermatitis usually 
resolves within three to four weeks after therapy (McQuestion, 
2006). 
 
Late effects can occur anywhere from 90 days to years after 
completing therapy as a result of permanent damage to the dermis 
(Harper, Franklin, Jenrette, & Aguero, 2004). 
 
• Late radiation-induced skin changes include atrophy, fibrosis, 
telangiectasias, and pigmentation changes.  
Radiation destroys fibroblasts in the dermis, resulting in 
reabsorption of collagen and tissue atrophy (Harper et al., 2004) 
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• Radiation-induced fibrosis is characterized by progressive 
induration, edema, and thickening of the dermis (Harper et al., 
2004). 
• Radiation also damages the vasculature of the dermal layer and 
blood vessels become prominent, dilated, and thin, also known 
as telangiectasias (Harper et al., 2004). 
• Irradiation exposure may destroy the dermal melanocytes, 
leading to hypopigmentation, or it may trigger the increased 
production of melanin in the skin, causing hyperpigmentation 
(Harper et al., 2004).  
 
CLINICAL PRESENTATION 
The assessment of radiodermatitis should utilize a validated 
assessment tool. The Radiation Therapy Oncology Group (RTOG) and 
the National Cancer Institute (NCI) have established similar assessment 
tools that classify radiodermatitis by severity. In brief, mild 
radiodermatitis (RTOG and NCI Grade 1) is characterized by mild, 
blanchable, erythema or dry desquamation. The onset is typically 
within days to weeks of initiating therapy and symptoms may fade 
within a month (McQuestion, 2006).  
 
Moderate radiodermatitis (Grade 2) is often painful and presents 
as edema and moist desquamation that is localized to the skin folds 
(Hymes, Strom, & Fife, 2006). In severe radiodermatitis (Grade 3 and 
4), the area of moist desquamation has spread to areas outside of the 
skin folds. Grade 4 radiodermatitis indicates that ulcers, hemorrhages, 
and/or tissue necrosis is present. Ulcers may be red with raised edges 
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with a red or black base (McQuestion, 2006). Unfortunately, ulceration 
is very painful and does not heal well (Gerlach, 2005). 
 
DIFFERENTIAL DIAGNOSIS 
The patient’s treatment history, specifically the duration of and 
cumulative dose of radiotherapy, will provide the best clue as to the 
diagnosis of radiodermatitis. However, there are several other 
differential diagnoses to consider that include radiation recall, cellulitis, 
eczema, and secondary malignancy (Chen et al, 2009; Yeo & Johnson, 
2000).  
 
Table 8: RTOG SCALE (Radiation Toxicity Oncology Group) 
 
The Radiation Oncology Group (RTOG) produced toxicity criteria which 
measures skin reactions.This is used in radiotherapy departments and can b
e classified into three levels. 
RTOG: 1 
 
Faint or dull erythema with epilation,  
decreased sweating, drying, reddening,tingling, 
itching and warmth.  
RTOG: 2 
 
Tender or bright erythema with patchy moist 
desquamation with moderate oedema.  
RTOG: 3 
 
Confluent moist desquamation, the inflamed 
epidermis may slough leaving painful denuded 
areas of dermis exuding serum.  
(Cox J.D. Stetz J. Patak T.F. 1995). 
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Table 9: RTOG Radiation Morbidity Scoring 
 
Onset   Grade    
 0 1 2 3 4 5 
Acute 
No change 
over base-line 
Follicular, faint 
or dull erythema/
 epilation/ dry 
desquamation/ 
decreased 
sweating 
Tender or 
Bright erythema. Patchy 
moist desquamation/ 
moderate  Edema. 
Confluent, 
Moist 
desquamation 
Other than skin 
folds. Pitting 
edema. 
Ulceration. 
Hemorrhage 
Necrosis 
n/a 
Chronic None Slight atrophy. Patch atrophy. Moderate 
telangiectasia. Total hair loss. 
Marked atrophy. Gr
oss telangiectasia. 
Ulceration Death 
 
Adapted from Radiation Therapy Oncology Group (2010) 
Table 2: NCI Radiation Toxicity 
 Grade    
0 1 2 3 4 
None Faint erythema/ dry 
desquamation 
Moderate erythema/ 
Patchy moist desquamation, 
confined to skin folds/ moderate
 edema 
Confluent moist 
Desquamation >1.5 
cm, not confined to 
skin folds/ pitting edema 
Ulceration or skin necrosis 
 
Adapted from National Cancer Institute (1999) 
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IMPROVING PATIENT OUTCOMES  
The successful outcome of oral mucositis treatment depends 
greatly on the patient’s proper use of medications. Methods to improve 
the use of medication can include  
 Patient counselling (education)  
 Determination of patient compliance with therapy. 
PATIENT COUNSELLING (EDUCATION)  
Patient counselling may be defined as an interactive session 
designed to educate the patient about the medication by providing 
complete information and identifying and removing barrier to 
appropriate therapy (Parthasarathy G, 2004). 
Effective patient counselling aims to produce the following results 
 Better patient understanding of their illness and the role of 
medication in its treatment 
 Improved patient compliance   
 Reduced incidence of adverse effects and unnecessary healthcare 
costs 
 Improved quality of life for the patient 
 Better coping strategies to deal with treatment related adverse 
effects 
 Improved professional rapport between the patient and 
pharmacist 
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PATIENT COMPLIANCE  
Compliance with medical treatment is one of the most significant 
global public health concerns facing society today. With cancer 
particular, there are an ever increasing number of patients burdened 
with the disease due to the ageing population profile and the social 
habits. Since the majority of cancer patients are being not aware of the 
radiation therapy and that its discontinuation may lead to an ineffective 
treatment, and the recurrence of tumor repopulation. Despite the 
availability of various treatments to cancer, poor compliance is found to 
occur due to the illiteracy and economic costs of the treatment.  
The term compliance is sometimes used interchangeably with 
adherence. They both describe the agreement between the medical 
regimen prescribed by the treating physician and actual patient 
practice. However, adherence implies a more active role of the patient 
in the process and indicates a responsibility of both parties to achieve 
success (Berg, 1993; Greenburg, 1984).  
Steps to improve patient compliance 
Improving adherence to treatment through patient education is 
important but not as practical or effective when performed by the 
physician alone. A multi-disciplinary approach involving the 
physician, technicians or nurses, social workers and pharmacists may 
be more effective. The multi-disciplinary intervention involves video- 
and brochure-based patient education; personalized counselling by a 
pharmacist, and regular follow-up telephone calls by a pharmacist. 
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Importance of cancer education 
 To create awareness that cancer is not a communicable disease 
among the relatives of the patients 
 To create an awareness about the treatments available to cancers, 
the beneficial effects that may supersede the side effects of the 
radiotherapy 
 Maintenance of proper oral hygiene during radiotherapy, 
particularly in case of head and neck cancers 
 Need for a planned proper nutritional diet during the 
radiotherapy treatment E.g. 
 To take high protein-rich foods 
 To avoid hot and spicy foods 
 To take soft foods and liquids that is rich in calories  
 Small frequent feedings are recommended when appetite is poor 
and when swallowing is difficult 
 Need for a regular follow up visit, to check for the tumor 
recurrence 
 Tobacco and alcohol use, which contributes to mucosal irritation 
and tumor repopulation should be strongly discouraged  
 Necessary screening and rehabilitation awareness should be 
created 
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GENERAL SKIN CARE ADVICE  
 
The following skin care guidelines are issued to all patients before the 
start of radiotherapy, and apply to the area being treated, including 
both the entry and exit sites.  
 
¾ Use lukewarm water and a non-perfumed, non-medicated soap.  
 
¾ Pat dry using a soft cloth, do not rub harshly.  
 
¾ Do not rub, scratch or scrub the treatment area.  
 
¾ If the axilla is within the treatment area shaving should be 
avoided.  
 
¾ Do not use flannels, loofahs or brushes on the treatment area.  
 
¾ Do not use perfumed skin products on the treatment area e.g. 
deodorants, aftershave or perfume.  
 
¾ Use a mild detergent (fragrance-free if possible) for washing 
clothing that will be worn next to the treatment area.  
 
¾ Wear soft loose cotton clothing over the treatment area, avoid 
straps or belts that may rub  
 
¾ Following mastectomy, if a permanent prosthesis causes 
increased friction and /or moisture a soft prosthesis should be 
used.  
 
¾ Do not use Elastoplasts or adhesive tape on the treatment area.  
 
¾ Do not apply heat e.g. hot water bottles or hot / cold packs to the 
treatment area. 
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PLATE 4 
Images of invasive breast cancer: 
Left: Pathology slide image of cancerous breast tissue, 
Right: Tumor (white area) in fatty breast tissue. 
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Basal Cell Carcinoma 
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      Microscopic image of a radio dermatitis lesion 
 
    
 
 
PLATE 10 
 
SKIN REATION APPEARANCE 
 
RTOG 1     RTOG 2 
 
           
 • Faint or dull erythema  • Patchy moist desquamation.  
                                                           • Moderate oedema. 
 
 
RTOG 3 
       
 
• Confluent moist desquamation. 
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2. DRUG PROFILE 
Amrad cream contains 
¾ Calendula 
¾ Chamomile 
¾ Aloe vera   
¾ Rubia cordifolia 
CALENDULA FLOWER 
 
 
                  
 
 
Figure : 3 
Biological Name: Calendula officinalis 
Overview: 
The flower petals of the calendula plant (Calendula officinalis), or 
pot marigold, have been used for medicinal purposes since at least the 
12th century. Calendula is native to Mediterranean countries but is now 
grown as an ornamental plant throughout the world. However, it is not 
the same as the annual marigold plant that’s often grown in gardens. 
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Plant Description: 
Calendula is an annual plant that thrives in almost any soil but 
can typically be found in Europe, Western Asia, and the United States. 
It belongs to the same family as daisies, chrysanthemums, and 
ragweed. Its branching stems grow to a height of 30 - 60 cm, and it 
blooms from early spring until frost. The orange-yellow petals of the 
flowers are used for medicine. 
Parts Used: 
The dried petals and leaves of the calendula plant are used for 
medicinal purposes. 
Active Compounds:   
The flavonoids, found in high amounts in calendula, account for 
much of its anti-inflammatory activity; triterpene saponins may also be 
important. Calendula also contains carotenoids.  
Medicinal Uses and Indications: 
Today, calendula is not usually taken by mouth. The exception is 
when it is used in extremely small amounts in homeopathic 
preparations. Calendula is usually applied topically, to the skin 
 It was used for treating boils, rashes, inflamed or damaged skin. 
 It reduces inflammation, swelling, itching and has antiseptic, 
astringent actions, and it is effective against acute dermatitis. 
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Burns, cuts, and bruises 
Calendula tinctures, ointments, and washes are often applied to 
the skin to help burns, bruises, and cuts heal faster, and to fight the 
minor infections they cause. Calendula cream is also used to treat 
hemorrhoids.  
Dermatitis 
Early evidence suggests that calendula may help prevent 
dermatitis -- skin inflammation -- in breast cancer patients who are 
undergoing radiation therapy, when compared with another lotion. 
However, the study wasn't double-blind, meaning the women knew 
whether they were using calendula or the other lotion. 
Available Forms: 
Fresh or dried calendula petals are available in tinctures, liquid 
extracts, infusions, ointments, and creams. Calendula products should 
always be protected from light and moisture, and should not be used 
after 3 years of storage. 
Pediatric 
• Use only topical and homeopathic preparations for children. 
• Calendula can be applied to the skin using a 2 - 5% ointment. 
• For homeopathic dosages, consult a licensed homeopath. 
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Adult 
• Infusion: 1 tsp (5 - 10 g) dried florets in 8 oz (250 ml) water; steep 
10 - 15 minutes; drink 2 - 3 cups per day 
• Fluid extract (1:1 in 40% alcohol): 0.5 - 1.0 ml 3 times per day 
• Tincture (1:5 in 90% alcohol): 5 - 10 drops (1 - 2 ml) 3 times per 
day 
• Ointment: 2 - 5% calendula; apply 3 - 4 times per day as needed 
Precautions: 
The use of herbs is a time-honored approach to strengthening the 
body and treating disease. Herbs, however, can trigger side effects and 
can interact with other herbs, supplements, or medications. For these 
reasons, you should take herbs with care, under the supervision of a 
health care provider. 
Possible Interactions: 
There are no known scientific reports of interactions between 
calendula and conventional or herbal medications. In theory, taking 
calendula orally may interact with the following medications, so talk to 
your doctor before combining these drugs with calendula: 
• Sedatives 
• Drugs to treat high blood pressure 
• Medications to treat diabetes 
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Traditional Uses in Herbal Medicine: 
Calendula flowers were believed to be useful in reducing 
inflammation, wound healing, and as an antiseptic. Calendula was 
used to treat various skin diseases, ranging from skin ulcerations to 
eczema. Internally, the soothing effects of calendula have been used for 
stomach ulcers and inflammation.  
Other indications include: 
• Antiseptic, anti-inflammatory, healing, and soothing. 
• Infusion of the petals used as lotion for skin cleansing and 
softening. 
• Taken internally for poor circulation, varicose veins, ulcers, 
colitis, stomach cramps; also, headaches, toothache, ague, and 
skin problems. 
• Said to strengthen and comfort the heart and aid indigestion. 
• For external use, an oil is made from the flowers for skin 
problems and sunburn; used in ointment form to heal acne and 
fade old scars and for external sores, cuts, bruises, burns and 
rashes. 
• Usually combined with chamomile and comfrey for a soothing 
ointment in cases of skin problems, burns, cuts, insect bites, 
stings and bruises. 
• An infusion from the leaves is used for tired swollen feet. 
• Flowers used in infusion form as a wash for red eye.  
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Dosage:  
 A tea of calendula can be made by pouring 200 ml of boiling 
water over 1-2 teaspoons of the flowers, which is steeped, 
covered for ten to fifteen minutes, strained, and then drunk. At 
least 3 cups of tea are generally drunk per day. 
 Tincture is similarly used three times a day, taking 1-2 ml each 
time. The tincture can be taken in water or tea.  
 Prepared ointments are often useful for skin problems, although 
wet dressings made by dipping cloth into the tea (after it has 
cooled) are also effective.  
 Juice: Take 1 tsp. At a time, always freshly pressed. 
 Tincture: To make, soak a handful of flowers in 0.5 quart 
rectified alcohol or whiskey for 5 to 6 weeks. A dose is 5 to 20 
drops. 
 Salve: Boil 1 oz dried flowers or leaves, or 1tsp fresh juice, with 1 
oz of lard. 
Alternative Names: 
Calendula officinalis; Garden marigold; Pot marigold 
Other Names: Marigold, garden marigold, holigold, Mary bud, pot 
marigold, Calendula 
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CHAMOMILE FLOWER 
 
           
     
 
 
Figure: 4 
 
Description  
Chamomile is a daisy-like flower, a member of the family 
Asteraceae (also called by its older name Compositae.) The active 
compounds in German and Hungarian chamomile are extracted and 
used in herbal remedies. Other varieties of the plant such as Roman or 
English Chamomile (Chamaemelum nobile), which contain similar 
compounds, are not used as often for herbal remedies. 
Other common name(s): German chamomile, Hungarian chamomile 
Scientific/medical name(s): Matricaria chamomilla, Matricaria recutita,  
Overview: 
German chamomile is an herb. People use the flower head of the 
plant to make medicine.German chamomile is used for intestinal gas, 
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travel sickness, stuffy nose, hay fever, nervous diarrhea, attention 
deficit-hyperactivity disorder (ADHD), fibromyalgia, restlessness, and 
trouble sleeping.  
Active constituents 
German chamomile promotes relaxation and reduces swelling 
(inflammation). German chamomile might reduce swelling by slowing 
the production of prostaglandins, leukotrienes, and histamines.  
 
Medicinal Uses 
 
• Upset stomach (dyspepsia), when a specific product (Iberogast, 
Medical Futures, Inc) that combines of German chamomile and other 
herbs is used. The combination includes German chamomile plus 
peppermint leaf, clown's mustard plant, caraway, licorice, milk 
thistle, celandine, angelica, and lemon balm.  
• Colic in breast-fed infants when used in combination with other 
herbs. A specific product containing 164 mg of fennel, 97 mg of 
lemon balm, and 178 mg of German chamomile (ColiMil, Milte Italia 
SPA) taken twice daily for a week seems to reduce crying in breast-
fed infants with colic. 
• Treating or preventing swelling and deterioration (mucositis) of the 
mouth lining caused by radiation therapy and some types of 
chemotherapy, when used as a mouth rinse. 
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Side effects 
German chamomile can cause allergic reactions in some people. 
It is in the same plant family as ragweed, marigolds, daisies, and other 
related herbs. 
When applied to the skin, German chamomile can cause allergic 
skin reactions. When applied near the eyes, German chamomile may 
cause eye irritation.  
 
Special Precautions & Warnings: 
 Pregnancy and breast-feeding: Not enough is known about the 
use of German chamomile during pregnancy and breast-feeding. 
Stay on the safe side and avoid use. 
 Allergies to ragweed or related plants: German chamomile may 
cause an allergic reaction in people who are sensitive to the 
Asteraceae/Compositae family of plants. 
 Hormone-sensitive condition such as breast cancer, uterine 
cancer, ovarian cancer, endometriosis, or uterine fibroids: 
German chamomile might act like estrogen in the body. 
Interactions 
¾ Birth control pills (Contraceptive drugs) : Some birth control 
pills contain estrogen. German chamomile might have some of 
the same effects as estrogen. But German chamomile isn't as 
strong as the estrogen in birth control pills.  
¾ Estrogens interacts with GERMAN CHAMOMILE : Large 
amounts of German chamomile might have some of the same 
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effects as estrogen. But large amounts of German chamomile 
aren't as strong as estrogen pills.Some estrogen pills include 
conjugated equine estrogens (Premarin), ethinyl estradiol, 
estradiol, and others. 
 
¾ Medications metabolized by the liver (Cytochrome P450 1A2 
(CYP1A2) substrates) interacts with German chamomile 
 
 Some medications are broken down by the liver. 
German chamomile might decrease the metabolism some 
medications.  
 These include amitriptyline, haloperidol, ondansetron, 
propranolol, theophylline, verapamil and others. 
 Benzodiazepines also interact with German chamomile. 
Also other sedatives Pentobarbital, phenobarbital, 
secobarbital, fentanyl morphine, zolpidem and others. 
 Tamoxifen interacts with GERMAN CHAMOMILE 
 
Dosing 
 
By mouth 
• For upset stomach: A specific combination product containing 
German chamomile (Iberogast, Medical Futures, Inc) and 
several other herbs has been used in a dose of 1 mL three times 
daily. 
• For damage to the inside of the mouth caused by chemotherapy 
or radiation treatments: A mouth rinse made with 10-15 drops 
of German chamomile liquid extract in 100 mL warm water 
three times daily. 
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ALOE VERA 
 
Figure: 5 
The aloe vera -A natural medicine for cancer, cholesterol, 
diabetes, inflammation, IBS, and other health conditions. 
In a single plant, aloe vera offers potent, natural medicine that: 
• Halts the growth of cancer tumors. 
• Lowers high cholesterol. 
• Repairs "sludge blood" and reverses "sticky blood". 
• Boosts the oxygenation of your blood. 
• Eases inflammation and soothes arthritis pain. 
• Protects the body from oxidative stress. 
• Prevents kidney stones and protects the body from oxalates in 
coffee and tea 
• Alkalizes the body, helping to balance overly acidic dietary 
habits 
• Cures ulcers, IBS, Crohn's disease and other digestive disorders. 
• Reduces high blood pressure naturally. 
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• Nourishes the body with minerals, vitamins, enzymes and 
glyconutrients. 
• Accelerates healing from physical burns and radiation burns. 
• Replaces dozens of first aid products, makes bandages and 
antibacterial sprays.    
• Halts colon cancer, heals the intestines and lubricates the 
digestive tract. 
• Ends constipation. 
• Stabilizes blood sugar and reduces triglycerides in diabetics. 
• Prevents and treats candida infections. 
• Protects the kidneys from disease. 
• Functions as nature's own "sports drink" for electrolyte balance 
• Boosts cardiovascular performance and physical endurance. 
• Speeds recovery from injury or physical exertion. 
• Hydrates the skin, accelerates skin repair. 
Aloe vera boosts immune function and destroys cancer tumors 
Scientific research shows strong immunomodulatory and 
antitumour properties for aloe vera polysaccharides. That means the 
gel helps boosts immune system function while destroying cancer 
tumors. One study published in International Immunopharmacology 
(1995) showed that aloe vera polysaccharides exhibited potent 
macrophage-activating activities including producing increased 
volumes of nitric oxide (which has antitumor potential). 
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Aloe vera halts inflammation 
Using aloe topically is well known to ease inflammation of joints, 
reducing arthritis pain. But aloe can also be used internally, reducing 
inflammation throughout the body from the inside out. People who 
drink aloe vera for two weeks typically begin to experience a significant 
reduction of inflammation symptoms. 
Aloe vera enhances skin health 
Aloe is one of the most widely-used ingredients in high-grade 
skin care products. There's a reason for that: It's great medicine for the 
skin! Aloe soothes the skin, hydrates it, nourishes it and accelerates the 
regeneration of new skin tissue 
Aloe vera stabilizes blood sugar in diabetics 
Diabetic patients who take aloe vera for 3 months experience a 
significant drop in fasting blood sugar levels. They also exhibit lower 
cholesterol levels and slight improvements in total cholesterol.  
Aloe vera lowers cholesterol and triglycerides 
When used internally, aloe vera gel improves the quality of the 
blood and helps rebalance the blood chemistry in a way that lowers 
cholesterol and total triglycerides (in people with elevated levels). 
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Aloe vera relieves joint and muscle pain 
This effect is directly related to the inflammation factor 
mentioned above. It works when used both internally and externally. 
Essentially, aloe reduces overall inflammation. 
Aloe vera amplifies the antioxidant effects of vitamins 
This is an especially interesting effect of aloe: It makes vitamin C, 
vitamin E and other antioxidants work better! It actually potentiates 
antioxidants, probably due to its effect on enhancing blood quality and 
allowing the blood to more effectively transport oxygen and nutrients 
to the body's cells  
Aloe vera cures ulcers, IBS, Crohn's disease and Celiac disease 
Polysaccharides in the aloe vera plant have curative effects on 
numerous digestive disorders. The Internet is a storehouse of 
information and testimonials about aloe vera curing IBS, ulcers, Crohn's 
disease and other disorders of the digestive tract.  
Aloe vera contains acemannan, a natural immune booster 
There's research being done now on the anti-cancer effects of 
acemannan, a phytonutrient found in aloe vera. In one study, dogs and 
cats undergoing radiation for cancer were given acemannan as an 
adjunctive therapy. 
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Aloe vera heals radiation burns from radiation cancer treatments 
For those cancers treatment victims who have been maimed by 
radiotherapy treatments, applying aloe vera topically to the radiation 
area will rapidly accelerate the healing response.  
The abstract states: 
Radiomodifying effects of the leaf extract of Aloe vera were 
observed on the testes of Swiss albino mice at 50 and 100 mg/kg dose 
levels. This extract was non-toxic when injected up to 800 mg/kg, and 
significant enhancement in survival time of the irradiated group was 
observed. In addition, treatment reduced radiation-induced damage to 
germ cells and loss in body weight. 
Contents of aloe vera gel 
• Water 
• 20 minerals 
• 12 vitamins 
• 18 amino acids 
• 200 active plant compounds (phytonutrients), including: 
              Enzymes 
              Triterpenes (a phytonutrient that lowers blood sugar) 
              Glyconutrients & glycoproteins 
              Polysaccharides, including: Acemannan, mannose-6-phosphate  
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RUBIA CORDIFOLIA 
 
      Figure: 6 
Rubia cordifolia, often known as Common Madder or Indian 
Madder, is a species of flowering plant in the coffee family, Rubiaceae. 
It has been cultivated for a red pigment derived from roots. 
Common names of this plant include Manjistha in Sanskrit, 
Marathi, Kannada and Bengali, Majith in Hindi and Gujarati, 
Tamaralli in Telugu, Manditti in Tamil. 
Description 
• It can grow to 1.5 m in height. The evergreen leaves are 5–10 cm 
long and 2–3 cm broad, produced in whorls of 4-7 starlike 
around the central stem. It climbs with tiny hooks at the leaves 
and stems. The flowers are small (3–5 mm across), with five pale 
yellow petals, in dense racemes, and appear from June to 
August, followed by small (4–6 mm diameter) red to black 
berries.  
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• The roots can be over 1 m long, up to 12 mm thick. It prefers 
loamy soils with a constant level of moisture. Madders are used 
as food plants for the larvae of some Lepidoptera species 
including Hummingbird hawk moth 
• Rubidianin, rubiadin, RA-7, RA-700 and RC-18 isolated from 
Rubia cordifolia inhibit growth & spread in cancers of breast, 
ovary, cervix, colon, lung, malignant ascites, malignant 
lymphoma, malignant melanoma sarcoma and leukaemia. 
Rubiadin also possesses hepatoprotective activity..  
• The plant grows throughout India, in hilly districts upto 3500 
meters height. It is a perennial, herbaceous climber. The stems 
are often long, rough and grooved, with woody base. The leaves 
often in whorls of four. They are 5-10 cm long, variable, cordate – 
ovate to cordate-lanceolate, rough above and smooth beneath. 
• The flowers, 0.3-2.5 cm long, blackish or greenish black, in 
terminal panicled glabrous cymes. The fruits are globose, fleshy, 
smooth, purplish black when ripe and shining. The roots are 4-8 
cm long, reddish, cylindrical, flexuous, with a thin red bark.  
• The botanical name of Manjistha is Rubia cordifolia and it belongs 
to family rubiaceae. The roots contain resinous and extractive 
matter, gum, sugar, coloring matter, - the salt of the pigment 
being a red crystalline principle purpurine.  
• Other compounds isolated are xantho-purpurin, glucose, sucrose 
and ruberythric acid. Alizarin, purpurin, purpurin carbohydrate, 
quinizarine and christofin isolated from roots. Antitumor cyclic 
hexapeptides – RA-V and RA-VII – isolated from roots.  
 
 
 
Drug Profile  
 
81 
 
Properties 
Manjistha is bitter, astringent and sweet in taste, pungent in the 
post digestive effect and has hot potency. It alleviates all the three 
doshas. It possesses dry and heavy (to digest attributes. It is a potent 
blood purifier and anti diarrhoeal.  
Pharmacologic properties 
The following properties were described in various cellular and animal 
models: 
 Anti-inflammatory 
 Urolithiasis  
Uses 
 It is used to treat skin infections,leucoderma  
 It helps to gain luster and glow of the skin to treat discoloration. 
 Externally, Manjistha is highly recommended in skin diseases 
associated with edema and oozing. The wound and ulcers 
dressed with Manjistha ghrta heal promptly and get dried up 
and well cleansed. Especially the chronic non-healing and 
cozying wounds respond very will.  
 In fractures, the external splint of Manjistha, madhuka skin and 
amalaki leaves are beneficial.  
 The root powder works well, with ghee, for the medicament of 
acne. Used externally as a paste by itself or with honey, it heals 
inflammation and gives the skin an even tone and smoothness. 
 
 
 
Drug Profile  
 
82 
 
 It is a powerful dye, imparting a reddish tinge to the skin and is 
used in dying the clothes also. Internally, Manjistha is valuable 
in a vast range of diseases. 
 In diarrhoea, Manjistha works well when combined with lodhra 
(Symplicos racemosa) skin powder. 
 Manjistha is benevolent in gastrointestinal ailments like loss of 
appetite, dyspepsia and worm infestations, as it is an appetizer, 
digestant, destroys ama and a vermicide.  
 Manjistha kvatha is widely used as a blood purifier. It acts 
mainly on rasa and rakta srotasas, alleviates the kapha and pitta 
dosas and eliminates toxins. This ameliorates the vitiation of 
bhrajaka pitta (pitta from the skin) and imparts better 
complexion to the skin. 
 Manjistha was held in high esteem by ancient sages in the 
treatment of skin diseases. It is widely used, till today, in various 
skin disorders like erysipelas, eczema, acne, scabies and allergic 
manifestations. 
 Manjistha helps in controlling the irritation of nerves and 
pacifies the mind, hence salutary in epilepsy, especially of pitta 
type. The decoction of manjistha, triphala, daruharidra, guduci, 
katuka, nimba and vaca is used in gout with benefit.  
 The cold infusion of Manjistha improves the menstrual bleeding 
and relieves the pain in dysmenorrheal. It stimulates and 
cleanses the uterus, so useful in postnatal ailments. The 
decoction of Manjistha is useful in oligomenorrhea and 
amenorrhea.  
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3. LITERATURE REVIEW 
LITERATURE SURVEY 
An extensive literature survey was carried out regarding 
“Prevention of radiation induced Radiodermatitis and its 
Management”. The necessary information collected from various 
literatures was documented. 
The literatures supporting the study were gathered from various 
sources such as Iowa Drug Information Services [IDIS], software 
released by the College of Pharmacy, University of Iowa &the division 
of Drug Information Services [DDIS] containing articles from about 250 
medical and related journals in & around the world. 
JOURNALS: 
The various journals used for references were 
¾ Annals of Pharmacotherapy 
¾ European  Journal of  Cancer 
¾ Journal of Clinical oncology 
¾ The Journal of Immunology 
¾ Gynecologic Oncology 
¾ Journal of Leukocyte 
¾ Clinical and Translational Oncology 
¾ Clinical Cancer Research 
¾ Radiotherapy and Oncology 
¾ The New England Journal of Medicine 
¾ Supportive Care in Cancer 
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¾ Southern Medical Journal 
¾ Cancer 
¾ Cancer Nursing 
¾ Caner Control 
¾ International Journal of Cancer 
¾ Journal of Pharmaceutical Sciences 
¾ International Journal of Clinical Pharmacy and Therapeutics 
¾ International Journal of  Radiation Oncology Biology Physics 
 
An extensive search for literature was done on important data bases 
like: 
¾ Medscape 
¾ The Lancet 
¾ Pubmed  
¾ Medline 
¾ Sciencedirect 
¾ Cancerlit 
¾ Radiation Oncology 
¾ The Cochrane Library 
¾ Pubget 
¾ CINAHL 
¾ DARE 
¾ HealthSTAR 
¾ South-East Asia Database 
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 H. C. Goldberg M.D et al., in 1944 suggested that a number of 
interesting articles have appeared giving quaint historical lore 
and scientific application of the Aloe Vera leaf for dermatologic 
purposes. Particular application of the leaf has been 
recommended in radio dermatitis. The first article published on 
the use of the Aloe Vera leaf in radio dermatitis was written by C. 
E. Collins and Creston Collins. Dr. C. E. Collins first became 
interested in the therapeutic use of the leaves in 1935, his son Dr. 
Creston Collins having seen the Seminole Indians using the leaf 
of the plant to treat burns. These physicians then applied the leaf 
for the treatment of radio dermatitis, with encouraging results. 
Since then, aloe Vera has become widely used for this purpose. 
 C. C. Lushbaugh M.D et al., in 1953 has done Experimental 
acute radio dermatitis following beta irradiation. V. 
Histopathological study of the mode of action of therapy with 
aloe Vera. Rabbits irradiated locally on the back with 14,000 and 
28,000 rep of beta radiation and the area was treated with the 
whole leaf of Aloe Vera and commercially available ointment 
made from these leaves. The gross and microscopic 
morphological changes in the skin resulting from the radiation 
alone were compared with those in the irradiated skin treated 
with Aloe. Treatment was found to hasten both the degenerative 
and reparative phases of the lesion so that complete healing of an 
ulcer caused by 28,000 rep of beta radiation was accomplished 
within two months of treatment, while the untreated ulcerations 
were still not completely healed more than four months after 
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irradiation. It was concluded that A. Vera contains substances 
that are stimulatory both to the relayed development and 
delayed healing of ulcerative radio dermatitis and that because 
of the growing modern importance of this injury further 
investigation of the action of aloe Vera should be pursued. 
 
 Cole et al., in 1935 reported that in 31 year old white women a 
case or severe roentgen dermatitis with desquamation over an 
area 4 by 8 cm of the forehead and extending above the hair line. 
Within 24 hours after the treatment with fresh aloe, the itching 
and burning had subsided completely. Within 5 weeks with 
continued treatment, there was complete regeneration of the 
skin of the forehead and scalp, new hair growth, complete 
restoration of sensation and absence of a scar. After 3 months 
there was no indication of a relapse and upon exposure to 
sunburn, the forehead was seen to be pigmenting normally along 
with other exposed skin surfaces . In 1937, Lovemen reported 
two cases of 40 year old man suffering from severe roentgen ray 
ulcers on the back of both hands. Treatment with fresh aloe leaf 
reduced ulceration area 50% within a week and completes 
healing within a few months. 
 
 Davis et al., in 1992 Aloe Vera is a complex plant containing 
many biologically active substances. Evidence has shown that 
Aloe is effective in wound healing and inflammation reduction 
.This is attributed to a growth factor-like substance in Aloe 
which activates the wound healing and inflammation reduction 
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process.Mannose-6-phosphate and glucose-6-phosphate are the 
main constituents of the polysaccharide chain in Aloe. Our 
experiments have shown that mannose-6-phosphate 
demonstrates wound healing and anti-inflammatory activity in a 
dose response fashion. Furthermore we concluded that glucose-
6-phosphate does not improve wound healing or reduce 
inflammation. Therefore, our evidence suggests that mannose-6-
phosphate is a major structural constituent that stimulates 
wound healing and anti-inflammation. In summation, we are 
convinced that M-6-P in aloe directly or indirectly stimulates 
fibroblast activation. Therefore, it is clear that M-6-P is an 
important factor in the wound healing process and plays a 
significant role in the biological activity of Aloe Vera. 
 
 Robert H. Davis et al., in 1988 demonstrated in Aloe Vera-A 
Natural Approach for Treating Wounds, Edema, and Pain in 
Diabetes. The Diabetic patient suffers from wounds, edema and 
pain. There was a diminished wound healing mechanism, 
insensitivity to pain perception, and altered fluid dynamics, 
resulting in a prolonged edema response. This study dealt with 
Aloe Vera (decolorized) as a mode of treatment to alleviate some 
of the consequences associated with diabetes. The results in each 
area tested were favorable. As an aid in promoting diabetic 
wound healing, tested groups treated with Aloe Vera displayed 
nearly a 100% increase in wound size reduction as compared to 
their untreated counterparts. In the area of analgesia, diabetic 
mice receiving Aloe Vera were able to tolerate a painful stimulus 
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a full 3 second longer than suitable controls without the total 
obliteration of responsiveness to stimuli. Additionally, 
physiologically normal mice treated with Aloe represented 
nearly 3 times the tolerance to painful stimuli as compared to 
untreated animals. As an Antiedemic agent, Aloe treated animals 
experience a five-fold reduction in the edema response as 
compared to untreated diabetic groups. Aloe Vera has been 
proven to be an effective agent in the treatment of wounds 
edema and pain associated with diabetes. 
 
 Carroll. S .Wright M.D et al., in 1936 has reported that Aloe 
Vera is used in the treatment of Roentgen ulcers and 
Telangiectasis. From the case reported, it would seem that x-ray 
ulceration, even of several years’ duration, will respond to the 
use of Aloe Vera. The permanence of results can be determined 
only by watching cases thus treated over a period of time. Little 
can be expected in the treatment of Telangiectasis as a result of 
irradiation beyond a smoothing and softening of the affected 
skin. The use of the fresh whole leaf of Aloe Vera in the 
treatment of Roentgen dermatitis was suggested by C. E. and 
Creston Collins. Early in 1935, they reported a case of a woman, 
aged 31, who had a severe Roentgen dermatitis of the left 
forehead following a depilating roentgen treatment. Various 
local treatments were tried without effect, and exfoliation and 
severe itching persisted at the treatment site. The patient 
received a local application of the fresh whole leaf of Aloe Vera 
to allay the itching. Within 24 hours the sensation of itching and 
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burning subsided and the condition progressively improved 
within the next 5 weeks and showed “complete regeneration of 
skin of the forehead and scalp, new hair growth, complete 
restoration of sensation, and absence of scars. 
 
 Zawahry M. et al., in 1973 reported the use of Aloe in treating 
leg ulcers and dermatoses. His report deals with Aloe’s use 
locally in chronic leg ulcers, seborrhea, acne vulgaris, alopecia 
(hair fall), and alopecia areata. Drawings of the plant found on 
the walls of ancient Egyptian temples show that its pulp was 
used externally for treatment of burns, ulcers and parasitic 
infections of the skin. Aloe Vera has been used with some 
success in the treatment of various dermatological conditions, 
radiation ulcers, internal diseases such as peptic ulcers and 
burns. Aloe Vera proved to have a stimulating effect on the rate 
of healing of chronic leg ulcers. They believe improvement in 
three patients treated can be attributed to improvement in the 
peripheral circulation which is deficient in such patients. The 
drug appears to stimulate hair growth and drying of seborrheic 
skin. Improvement was noted after treatment of patients with 
seborrheic alopecia, acne vulgaris and alopecia areata. 
 
 World Health Organization in 1999 published Monographs on 
selected medicinal plants, including Aloe Vera which states that 
aloe Vera Gel is widely used for the external treatment of minor 
wounds and inflammatory skin disorders. The gel is used in the 
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treatment of minor skin irritations, including burns, bruises, and 
abrasions. Aloe Vera has been effectively used in the treatment of 
first and second degree thermal burns and radiation burns. Both 
thermal burns and radiation burns healed faster with less 
necrosis when treated with preparations containing Aloe Vera 
Gel. Healing of radiation ulcers was observed in two patients 
treated with Aloe Vera cream. Complete healing was observed, 
after treatment with fresh Aloe Vera Gel, in two patients with 
radiation burns. Twenty-seven patients with partial thickness 
burns were treated with Aloe Vera Gel in a placebo-controlled 
study. The Aloe Vera Gel-treated lesions healed faster (11.8 days) 
than the burns treated with petroleum jelly gauze (18.2 days), a 
difference that is statistically significant (t-test, P < 0.002). 
 
 W. R. Sage, Inc et al., in 1977 reported that in both medical and 
cosmetic practices, the Aloe Vera plant was used consistently 
through the centuries for such varied conditions as wounds, 
stomach disorders, headaches, gum and mouth disease, 
constipation, hemorrhoids, kidney problems, insomnia, pruritis, 
burns, dermatitis, herpes, fungal infections, loss of hair, 
indigestion, insect stings, dysentery, prostatitis, colds and body 
odors. Some of the earliest scientific research was performed in 
1935 by researchers for the Atomic Energy Commission. They 
concluded that Aloe Vera was the most effective product known 
for the treatment of radiation burns of the skin.  
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 In 2004 Anatomy of an ingredient: Aloe Vera published by The 
Independent, London THE ALOE plant consists of around 400 
different species, and was first originated in Africa. The type of 
Aloe grown commercially in America (North and South), Asia, 
Africa, Australasia and southern Europe, is the Aloe Barbadensis 
Miller plant, known as aloe Vera - Latin for "true aloe”. This 
exceptional plant contains a wide range of amino-acids, 
enzymes, minerals, vitamins and other micronutrients. The sap 
of the aloe contains substances called anthraquinones that have 
antibacterial, antiviral, antifungal, anti-inflammatory, analgesic 
and anaesthetic properties. It boosts the immune system, 
provides antioxidant vitamins A, C and E, helps healing, 
lubricates joints, and is an effective tonic. Aloe Vera can be used 
on the skin, to treat rashes, sunburn, dermatitis, eczema and 
psoriasis. It can also be taken internally, and is useful for 
conditions like colitis, arthritis, IBS, asthma, and chronic fatigue. 
Opt for Aloe Vera products that are listed as 98-99 per cent pure, 
as these will be higher in the protective mucopolysaccharides 
that have a healing effect on the gut. 
 
 Srinivas, C.R. et al., in 2003 aggravated the pre-existing 
dermatosis with Aloe Vera. A 65-year-old man presented with 
recurrent generalized itching since 1 year. Examination revealed 
lichenified skin over the face and extensors of both extremities. 
He gave a history of rubbing the pulp of Aloe Vera leaves on to 
his lesions whenever his itching worsened. Clinically, we 
suspected allergic contact dermatitis, possibly aggravated with 
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Aloe Vera. He was patch tested with the plant series by CODFI, 
which included parthenium 0.5%, xanthium 0.5%, 
chrysanthemum 0.5%, control and pulp of Aloe Vera, and the 
results were interpreted as recommended by ICDRG. He tested 
positive to Aloe Vera on day 2 and day 3. One of the authors 
(CRS) tested negative to the pulp, thus ruling out irritant 
dermatitis. Allergic contact dermatitis to Aloe Vera has been 
reported earlier. The gelatinous material inside the leaf of Aloe 
Vera has been recommended from ancient times for the 
alleviation of inflammatory changes in the skin. More recently it 
has been advocated in the treatment of radio dermatitis and leg 
ulcers. It is a common ingredient in numerous topical 
moisturizers (e.g. Elovera, Sofderm, and Dewderm). Aloe 
consists of a variable mixture of aloin, aloemodin and other 
substances. Aloin is an anthraquinone that may be regarded as a 
potential sensitizer. This report highlights the fact that even 
commonly used; relatively safe medications can occasionally 
cause sensitivity. 
 
 Momoe Soeda et al., in 1964 has done studies on the effect of 
Cape Aloe for irradiation leucopenia. Studies on the prophylactic 
and therapeutic effects on leucopenia caused by exposure to 
Cobalt-60, and studies on protective and therapeutic effect of 
Marinamycin against leucopenia in X-ray irradiated rabbits were 
reported by SOEDA and Solcoseryl was also used for evaluation. 
In the course of studies and prophylactic and therapeutic effects 
of aloelin and aloe-B fraction on leucopenia induced by Cobalt-
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60 irradiation, some impressive findings were derived there 
from, the reports of which is herein described. Therapeutic 
intravenous and subcutaneous administration of aloelin and aloe 
B fractions five or seven consecutive days in dosage ranging 100 
mcg rabbit subsequent to the whole body irradiation of Cobalt 
resulting in improving the WBC counts. 
 
 Smoot, E. Clyde (MD) et al., in 1981 deals with the effects of 
anti-inflammatory agents on acute and late radiation skin 
changes in the rat. This article by the University of Chicago 
Burn Center deals with one of the earliest recognized benefits of 
Aloe Vera. Back in the thirties, when x-Ray treatments were first 
being used, medical reports showed that Aloe Vera was the only 
thing that would heal many of the radiation induced lesions of 
the skin. Now, with this testing on rats, the data is established in 
true, scientific testing. The purpose of the study is to examine 
pharmacological methods of altering acute and late skin changes 
secondary to irradiation and to evaluate the role of 
prostaglandins and thromboxane as mediators of acute and late 
radiation skin pathology. Acute radiation changes in human skin 
include endothelial swelling and proliferation with thrombosis 
of larger dermal vessels. He has noted the limitation of 
progressive dermal ischemia after thermal injury to the skin of 
guinea pigs by inhibiting the local accumulation of thromboxane 
in radiation pathology. Vascular occlusive changes with 
resulting skin ischemia precede later changes of increased 
collagen deposition. Attenuation of the acute inflammatory 
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changes of radiation exposure may be expected to decrease 
chronic ischemic changes in the skin.  
 
 Murray, Frank et al., in 1994 demonstrated the Therapy and 
treatment with Aloe Vera. Researchers around the world, Texas, 
Japan, Israel are hard at work analyzing the many medicinal 
properties of the approximately 600 varieties of Aloe plants, 
which are being used successfully to treat burns, X-ray and 
radiation dermatitis, gastric ulcers, sunburn, frostbite, GI 
disorders, constipation, diabetes, etc., It penetrates injured tissue, 
relieves pain, is Anti-inflammatory and dilates capillaries, 
thereby increasing the blood supply to the injured area. They 
found that partial thickness burn wounds treated with Aloe 
extracts healed faster and had les tissue loss than patients treated 
with standard techniques. The researchers explained that Aloe 
inhibits a devastating vasoconstrictor known as TxA2 and keeps 
it from being produced, while maintaining a balance between 
several prostaglandins, the powerful hormones that impact on 
pain, healing etc., Aloe juices and gels have been shown to have 
antibacterial and antifungal properties and they appear to be 
active against a broad spectrum of microbes. Salicylate, which 
have both anti inflammatory and pain killing characteristics are 
found in Aloe also Magnesium lactate, a substance which can 
inhibit histamine reactions like itching and irritation, and 
enzymes of  bradykinin inhibitor are presented. Bradykinin 
produces pain in inflamed tissue.  
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 Mandeville, Frederick B. (MD) et al., in 1939 has done the study 
on Aloe Vera in the treatment of radiation ulcers of mucous 
membranes. It is reported that the jelly is placed in contact with 
the floor of the ulcer and held in place with the bandage. 
Dressings are changed once or twice daily. The treatment seems 
to be effective in indolent roentgen and radium ulcers. Often the 
pain disappears within a day or two and healing takes place in a 
few weeks or a few months. Good results have been obtained 
also in ulcers that occurred early in third-degree ulcers. A 54 year 
old male had noticed a growth 1 cm in diameter on the right side 
of his tongue and floor of his mouth anteriorly for three months. 
This was removed by a surgeon with electrocautery and the 
pathologist diagnosed as squamous cell epithelioma grade 3. 
Intra oral radium therapy heavily filtered and external deep x-
ray therapy was administered over a ten day period. The ulcer 
was deep and measured 5x1.5 cm. Aloe Vera gel was applied by 
the patients. Relief from pain was prompt and definite and the 
ulcer slowly grew smaller, after another five weeks the ulcer was 
completely healed. They concluded that Radiation ulcers of the 
mucous membranes and adjacent tissues of body cavities may 
also be treated with the fresh leaf of Aloe Vera. 
  
 Loveman, Adolph B. (MD) et al., in 1937 reported that Aloe 
Vera in used in the treatment of Roentgen ray ulcers. He has 
reported that two cases of roentgen ray ulcers are reported in 
which complete healing followed the use of the fresh whole leaf 
of Aloe Vera. The duration of the ulcer is important with regard 
to immediate prognosis. In the two cases under consideration 
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pain disappeared and healing occurred much sooner in the ulcer 
which had been present the shorter period of time. It is felt that 
treatment should be continued with the fresh whole leaf for 
atleast from three to nine months before the condition is 
considered refractory or the treatment is discontinued. In the two 
cases reported the fresh whole leaf of Aloe Vera proved to be 
much more efficacious than the ointments including bismuth 
subnitrate and neoarsphenamine in the treatment of the ulcer. 
The latter, however, was fairly satisfactory in treating some of 
the smaller keratoses and in improving the general tone and 
texture of the skin. In both cases there were marked increase in 
pain and definite progression in the size of the ulcerations while 
pavaex treatment was used.  
 
 Skousen, Max B et al., in 1982 published in his Hand Book, The 
Ancient Egyptian Medicine Plant that Aloe Vera has about one 
and half million species and one-fourth of the two billion 
prescriptions filled in the United States contain botanical 
derivatives such as alkaloids, Glycosides, Steroids etc., In the first 
century it is reported that Aloe Vera has been effectively used to 
treat burns, healing wounds, insomnia, constipation, GI 
disorders. Los of hair gum and mouth disorders blistering, sun 
burn, blemishes, ulcerated skin lesions, eczema and relieving 
aches and pains and it reduces the itching and scaling and 
greatly improving the skin appearance. The recent history 
reveals that Aloe Vera is highly effective in skin ulcerations 
caused by radiation burns. It is also reported that Aloe Vera is 
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used for cuts and wounds, digestive problems, hair and scalp 
care, hemorrhoids and bleeding piles, infections, poison ivy, 
poison oak, allergies, psoriasis and eczematous rashes, scar 
removal, stretch marks from pregnancy, varicose veins, skin 
cancer, scrapes and abrasions, stings by insects, jellyfish, stinging 
nettle, etc., ulcers, arthritis, brown skin spots, acne, animal first-
aid, sinus, general health maintenance, asthma, sore throat, eye 
and ear drops. 
 
 Danhof, Ivan E. (PhD, MD) et al., in 2002 demonstrated in his 
book Internal uses of Aloe Vera; the anti-cancer activity was 
explained that one of the common experimental cancer models is 
sarcoma-180. When Aloe was administered to mice bearing S-180 
tumors, the tumor growth was inhibited. Similarly, Alexin B, a 
species derived from Aloe, was shown to possess anti-cancer 
activity against lymphocytic leukemia. Additional investigations 
revealed that another molecular species derived from Aloe, 
Aloctin-A, had anti-tumor activity, but the action was to bolster 
the immune system rather than a direct anti-tumor activity. 
 
 Richardson  J et al., in 2005 has done a study to systematically 
review and critically appraise the evidence for effectiveness of 
Aloe vera gel for radiation-induced skin reactions. Major  
biomedical databases and specialist complementary and 
alternative medicine databases were searched. Relevant 
research was systematically categorised by study type and 
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appraised according to study design. He concluded that there 
is no evidence from clinical trials to suggest that topical Aloe 
vera is effective in preventing or minimising radiation-induced 
skin reactions in cancer patients. Further methodologically 
rigorous research studies should be conducted to evaluate the 
effectiveness of currently used and novel therapies for the 
prevention, minimisation and management of radiation-
induced skin reactions. 
 
 Mihkaila Maurine et al., in 2004 has done a study to review 
historical and current research data on prevention and 
treatment of acute radiation dermatitis. His data synthesis 
reveals that Washing the skin with mild soap and water and 
the hair with mild shampoo is safe during radiation therapy. 
Biafine (Medix Pharmaceuticals, Inc., Largo, FL), almond 
ointment, topical vitamin C, and gentian violet have not been 
proven effective and should not be used. Aloe vera is beneficial 
and also they are not harmful. He concluded that Nurse 
clinicians and nurse scientists must partner to conduct further 
research about the prevention and management of acute 
radiation dermatitis and develop comprehensive evidence-
based clinical practice guidelines. 
 
 Sue Heggie et al in 2002 has done a Phase III study on the 
efficacy of topical aloe vera gel on irradiated breast tissue. The 
aim of the study was to see if topical aloe vera gel would be 
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beneficial in reducing the identified skin side-effects of 
radiation therapy, including erythema, pain, itching, dry 
desquamation, and moist desquamation, when compared with 
aqueous cream. Patients were randomized to either topical aloe 
vera gel or topical aqueous cream to be applied 3 times per day 
throughout and for 2 weeks after completion of radiation 
treatment. Weekly skin assessments were performed by 
nursing staff. Aloe vera gel did not significantly reduce 
radiation induced skin side effects. Aqueous cream was useful 
in reducing dry desquamation and pain related to radiation 
therapy. 
 
 Olsen DL et al., in 2001 has done a study on the effect of aloe 
vera gel/mild soap versus mild soap alone in preventing skin 
reactions in patients undergoing radiation therapy. The 
purpose of the study was to determine whether the use of mild 
soap and aloe vera gel versus mild soap alone would decrease 
the incidence of skin reactions in patients undergoing radiation 
therapy. The mean age of the participants was 56 years. The 
group consisted of Caucasians (74%) and African Americans 
(26%). The ethnic mix was non-Hispanic (65%) and Hispanic 
(35%).His findings was at low cumulative dose levels < or = 
2,700 c Gy, no difference existed in the effect of adding aloe. 
When the cumulative dose was high (> 2,700 c Gy), the median 
time was five weeks prior to any skin changes in the aloe/soap 
arm versus three weeks in the soap only arm. When the 
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cumulative dose increases over time, there seems to be a 
protective effect of adding aloe to the soap regimen. 
 
 M S Williams et al., in 1996 has done a Phase III double-blind 
evaluation of an aloe vera gel as a prophylactic agent for 
radiation-induced skin toxicity. The purpose of the study was 
Considerable pilot data and clinical experience suggested that 
an aloe vera gel might help to prevent radiation therapy-
induced dermatitis. Two Phase III randomized trials were 
conducted. The first one was double blinded, utilized a placebo 
gel, and involved 194 women receiving breast or chest wall 
irradiation. The second trial randomized 108 such patients to 
aloe vera gel vs. no treatment. Skin dermatitis was scored 
weekly during both trials both by patients and by health care 
providers. The results revealed that Skin dermatitis scores were 
virtually identical on both treatment arms during both of the 
trials. The only toxicity from the gel was rare contact 
dermatitis. So he concluded that this dose and schedule of an 
aloe vera gel does not protect against radiation therapy-
induced dermatitis.  
 
 Maurene McQuestion Semin et al., in 2011has given Evidence-
based skin care management in radiation therapy: clinical 
update. The purpose of the study was to present a clinical 
update on the available evidence for the prevention and 
management of radiation skin reactions (radio dermatitis). 
There continues to be insufficient evidence in the literature to 
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recommend a variety of topical or oral agents in the prevention 
of skin reactions. Radiation treatment techniques are the most 
promising intervention in reducing the degree of skin reaction. 
The use of calendula cream may reduce the incidence of grade 
2 or 3 reactions in women with breast cancer. Oncology nurses 
need to be aware of the evidence and lack of evidence when 
recommending interventions to their patients and avoid undue 
marketing influence when suggesting interventions for the 
management of skin reactions. Further research is required to 
evaluate specific interventions in both the prevention and 
management of radiation dermatitis.  
 
 
 Benomar S et al., in 2010 has done a study on Treatment and 
prevention of acute radiation dermatitis. He observed that 
acute radiation dermatitis is a common side-effect of 
radiotherapy which often necessitates interruption of the 
therapy. Currently, there is no general consensus about its 
prevention or about the treatment of choice. The goal of this 
work was to focus on optimal methods to prevent and manage 
acute skin reactions related to radiation therapy and to 
determine if there are specific topical or oral agents for the 
prevention of this acute skin reaction. The prevention and the 
early treatment are the two focus points of the management of 
the acute radiation dermatitis. 
. 
 Maurene McQuestion Semin et al., in 2006 has given 
Evidence-based skin care management in radiation therapy. 
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The objective of the study was to review published studies 
evaluating interventions for the prevention and management of 
radiation skin reactions/dermatitis. He concluded that there is 
insufficient evidence in the literature to recommend specific 
topical or oral agents in the prevention or management of skin 
reactions. Recent limited evidence suggests that the use of 
calendula cream may reduce the incidence of grade 2 and 3 
reactions in women with breast cancer. Additionally, early 
studies evaluating the use of barrier films or creams may 
improve moist desquamation. 
 
 Amanda Bolderston et al.,in 2006 has given The prevention 
and management of acute skin reactions related to radiation 
therapy: a systematic review and practice guideline. The goal of 
the work is to find the optimal methods to prevent acute skin 
reactions (occurring within the first 6 months of irradiation) 
related to radiation therapy and its management. Cancer Care 
Ontario's Supportive Care Guidelines Group (SCGG) 
conducted a systematic review of literature. Twenty-eight trials 
meeting the inclusion criteria were identified. Of the twenty-
three trials that evaluated preventative methods, Some 
evidence suggested topical steroid creams and calendula 
ointment might be effective.  
 
 
 Pommier P et al., in 2004 has done a Phase III randomized trial 
of Calendula officinalis compared with trolamine for the 
prevention of acute dermatitis during irradiation for breast 
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cancer. The goal of this study was to compare the effectiveness 
of calendula (Pommade au Calendula par Digestion; Boiron 
Ltd, Levallois-Perret, France) with that of trolamine (Biafine; 
Genmedix Ltd, France), which is considered in many 
institutions to be the reference topical agent.He concluded from 
the study that Calendula is highly effective for the prevention 
of acute dermatitis of grade 2 or higher and should be 
proposed for patients undergoing postoperative irradiation for 
breast cancer 
.  
 Clavère P et al., in 2008 has proposed Radiation induced skin 
reactions which stated that Radiotherapy is one of the most 
important treatment modality of cancers. Skin secondary 
effects are well known. Cutaneous complications are 
described. Physiopathogenic mechanisms are reported. Many 
preventative and treatment options have been used with 
varying degrees of evidence of success. Information of patients, 
further research studies and a multidisciplinary approach are 
necessary to increase the management of radiation induced 
skin reactions. 
 
 Maenthaisong R et al., in 2001 has given the efficacy of aloe 
vera used for burn wound healing: a systematic review. Aloe 
vera has been traditionally used for burn healing, The purpose 
of the study was to conduct a systematic review to determine 
the efficacy of topical aloe vera for the treatment of burn 
wounds. Only controlled clinical trials for burn healing were 
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included. Four studies with a total of 371 patients were 
included in this review. Based on a meta-analysis using 
duration of wound healing as an outcome measure, the 
summary weighted mean difference in healing time of the aloe 
vera group was 8.79 days shorter than those in the control 
group (P=0.006). Cumulative evidence tends to support that 
aloe vera might be an effective interventions used in burn 
wound healing for first to second degree burns. 
 
 
 Feily A et al., in 2009 Aloe vera in dermatology: a brief review. 
Aloe vera Linne or aloe barbadensis Miller is a succulent from 
the Aloe family (400 different species), a tropical plant which is 
easily grown in hot and dry climates and widely distributed in 
Asia, Africa and other tropical areas. The aim of this systematic 
review was to summarize all dermatology-oriented in vitro and 
in vivo experiments and clinical trials on aloe vera 
preparations. Extensive literature search were carried out to 
identify all in vitro and in vivo studies as well as clinical trials 
on the subject. Forty studies were located. The results suggest 
that oral administration of aloe vera in mice is effective on 
wound healing, can decrease the number and size of 
papillomas and reduce the incidence of tumors and leishmania 
parasitemia by >90% in the liver, spleen, and bone marrow. . It 
can also be used as a biological vehicle and an anti-microbial 
and antifungal agent and also as a candidate for photodynamic 
therapy of some kinds of cancer. 
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 Hosseinimehr SJ et al., in 2010 has given the Effect of aloe 
cream versus sulfadiazine for healing burn wounds in rats. The 
aim of the study was to evaluate the efficacy of aloe vera cream 
in the treatment of thermal burn wounds and to compare these 
results with silver sulfadiazine in rats. Animals were divided 
into 4 groups and administered topical cream at 24hr of burn 
injury induced by hot water. On 25th day wound size was 
significantly smaller in aloe group as compared with other 
groups. The result of the study showed aloe cream to 
significantly increase re-epithelialization in burn wounds as 
compared with silver sulfadiazine.  
 
 Reuter J et al., in 2008 has done the study of Investigation of 
the Anti-Inflammatory Potential of Aloe vera Gel (97.5%) in 
the Ultraviolet Erythema Test. 40 volunteers with skin type II 
and III were included in the randomized, double-blind, placebo 
controlled, phase III monocenter study. The result was aloe 
vera gel(97.5%)significantly reduced UV-induced erythema 
after 48h,being superior to 1% hydrocortisone in cream was 
more efficient than aloe vera gel. He concluded that aloe vera 
gel tested might be useful in the topical treatment of 
inflammatory skin conditions such as UV-induced erythema. 
 
 Khorasani G et al., in 2009 conducted this clinical study, Aloe 
versus silver sulfadiazine creams for second-degree burns: a 
randomized controlled study to evaluate the efficacy of aloe 
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vera ream for partial thickness burn wounds and compare its 
results with those of silver sulfadiazine. 39 patients with II 
degree burns at two sites on different parts of the body were 
included in this study where one side treated with SSD and 
other with aloe cream. The result clearly demonstrated the 
greater efficacy of aloe cream over SSD cream for treating 
second degree burns.  
 
 Srivastava JK et al., in 2009 has done the study of Chamomile, 
a novel and selective COX-2 inhibitor with anti-inflammatory 
activity. Inducible cyclooxygemase (cox-2) has been implicated 
in the process of imflammation and carcinogenesis. 
Chamomile has long been used in traditional medicine for the 
treatment of inflammatory diseases. The aim of the study was 
to investigate whether chamomile interferes with the COX-2 
pathways. The data suggest that chamomile works by a 
mechanism of action similar to that attributed to non-steroidal 
anti-inflammatory drugs. 
 
 Hamman JH et al., in 1998 mentioned that many of the health 
benefits associated with Aloe vera have been attributed to the 
polysaccharides contained in the gel of the leaves. These 
biological activities include promotion of wound healing, 
antifungal activity, hypoglycemic or antidiabetic effects anti-
inflammatory, anticancer, immunomodulatory and 
gastroprotetive properties. While the known biological 
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activities of aloe vera will be briefly discussed. It is the aim of 
this review to further highlight recently discovered effects and 
applications of the leaf gel. These effects include the potential 
of whole leaf or inner fillet gel liquid preparations of aloe vera 
to enhance the intestinal absorption and bioavailability of co-
administered compounds as well as enhancement of skin 
permeation. 
 
 Crewe, J.E. (MD) et al., in 1937 experimentally proved in his 
work “The External uses of Aloe Vera” that the fresh leaves of 
Aloe Vera have many properties which includes, they relieve 
pain, itching and burning, they have some sort of antiseptic 
action, infected lesions quickly become clean and exude little or 
no pus, they seem to stimulate rapid granulation and formation 
of new tissue so that denuded areas appear to heal more rapidly 
than with other agents. They are effective in eliminating the foul 
odors that accompany infection of broken down carcinomas, 
ulcers and so forth. A single individual after amputation on the 
stumps of the legs with several ulcers and the condition of 
developed lymphedema was treated with the Aloe leaves. The 
circulation in the stumps was poor and several large ulcers had 
developed. They had shown no inclination to heal under various 
kinds of treatment. The ulcers were deep and measured to be 5by 
13cm and 3cm in diameter. Within twenty-four hours after 
application of the leaf of Aloe Vera, pain had practically 
disappeared and the edema was much reduced. The smaller 
ulcers healed in about two weeks, leaving practically no scar. 
The large ulcers also made good progress. 
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[ 
 Castillo, Rafael (MD). (N.D.) et al in 1968 revealed in his work 
“Aloe Vera in treating cancer” that he came across several 
literature and commentaries from cancer specialists on the 
potential anti cancer effects of Aloe Vera. The potential for 
natural cancer therapy with supplements like aloe Vera and 
melatonin has been suggested and these substances, called 
immunomodulants, may benefit certain forms of cancer. A health 
history of 100 cancer patients who use aloe Vera therapy as a 
part of their cancer treatment was reviewed, it is found that they 
receive gluconutrients and experience a reduction in size of 
squamous cell carcinomas (lung) and oat cell carcinomas 
(usually originate in the bronchi or lungs). The normal cells 
appeared protected and abnormal cells appeared more sensitive 
to treatment when aloe vera was made part of an integrated 
approach. 
 
 Robert H.Davis et al., in 1987 concluded in his study Aloe vera 
and wound healing that Wound healing and inflammation in 
patients present a major problem for podiatrists in the treatment 
of foot  condition. Pressure on skin from tight shoes causes ulcers 
that heal with difficulty. Heavy steroids and strong synthetic 
drugs provide major drawbacks because they inhibit wound 
healing and increase the spread of infection. The present data 
clearly indicate that Aloe in small doses improves circulation and 
wound healing. The decolorized Aloe vera (without 
anthraquinones) was more active than the colorized powder. 
Because of these results, the authors recommend Aloe vera for 
the wounds. 
 
 
 
Literature Review   
 
109 
 
 
 Vogler BK et al in 1999 conducted a systematic review of its 
clinical effectiveness. The aim of the study is to define the clinical 
effectiveness of aloe vera. The use of aloe vera is being promoted 
for a large variety of conditions. Four independent literature 
searchers were conducted in MEDLINE, EMBASE, BIOSIS, and 
the Cochrane Library. Only controlled clinical trials were 
included. Ten studies were located, they revealed that topical 
application of aloe vera is not an effective preventative for 
radiation- induced injuries. Even though there are some 
promising results, clinical effectiveness of oral or topical aloe 
vera is not suffiently defined at present. 
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4. SCOPE OF THE STUDY 
 
The scope of the present study is that cancer is one of the leading 
causes for death among population. Radiotherapy (RT) is used in a 
wide variety of pelvic malignancies. Radiotherapy alone or combined 
with cytotoxic therapy and/or surgery is also regarded as standard 
treatment at a number of primary tumor sites in the various parts of the 
body.  
 
Although the benefits of this treatment have been well 
established, a number of patients experience distressing complications 
due to radiation injury. 
 
Many of the patients undergoing radiation therapy have the 
complaint of skin toxicity complications. 
 
This may include acute symptoms such as Erythema, Epilation, 
Desquamation, Edema, Pain, Pigmentation changes etc occurs and in 
chronic the conditions such as Telangiectasia, ulceration occur. 
 
In some cases, these symptoms resolve after the cessation of 
radiation but many patients develop chronic illness causing adverse 
effects that leads to discomfort and decrease the benefits of 
radiotherapy treatment. 
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The herbal cream which is composed of four main 
therapeutically highly valuable drugs has been found to be useful and 
much safer than other creams in the prevention of  skin toxicity 
complications caused due to  radiation therapy. 
 
Amrad cream has the following features: 
 Aloe vera in AMRAD Cream increases re-epithelization of 
wounds enhances skin permeation and demonstrates greater 
efficacy over other creams. 
 Calendula in AMRAD Cream decreases Grade 2 or higher 
Radiation Dermatitis and reduces the incidence of treatment 
breaks. 
 Chamomile in AMRAD Cream is a novel and selective COX-2 
inhibitor with anti-inflammatory and anti-neoplastic effect. 
 Rubia cordifolia in AMRAD Cream promotes the healing of the 
skin tissues and aids in gaining luster and glow of the skin. 
 
Hence apart from the several approaches to decrease the skin 
complications, this study promises to be the evidence in preventing 
skin complications in radiation injured cases by applying the Amrad 
cream. 
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5. AIM AND OBJECTIVES 
 
AIM 
 The aim of the study is to investigate the efficacy of the herbal 
cream AMRAD in the management of radio dermatitis in Cancer 
patients. 
 
OBJECTIVES 
 
• To  assess  the  efficacy  of  Amrad cream   in  decreasing  the   
incidence  and   severity  of  the skin toxicities. 
• To measure the skin toxicities by grading according to the skin 
toxicity assessment tools-radiation therapy oncology group 
(RTOG) and National cancer institute (NCI).    
• To monitor any adverse drug reaction. 
• To provide effective counseling to the cancer patients. 
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6. PLAN OF THE WORK 
 
The entire study was planned to be carried out for a period of 
nine months from June 2011 – Feb 2012. The proposal was designed as 
given below. 
 
June’11 – July’11: 
9 Obtaining consent from the hospital authorities 
9 Literature survey 
9 Study design including study design of data entry format 
(Proforma) 
9 Obtaining approval from Institutional Ethics Committee (IEC) 
Aug’11 – Dec’11:  
9 Selection of patients 
9 Obtaining consent from patients 
9 Collection of patient details 
9 Collection of Lab reports 
9 Data Collection 
Jan’11 – Feb’12: 
9 Data compilation 
9 Statistical analysis 
9 Data correlation 
9 Submission of report 
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7. METHODOLOGY 
 
STUDY TYPE   : Intentional and Retrospective. 
CASUALTY ASSESSMENT : RTOG - radiation therapy  
Oncology Group  
                                                      NCI – National cancer institute 
SAMPLE SIZE   : 60 patients with AMRAD 
                             60 patients with control 
                            Totally 120 patients 
Patient selection   : 
• Inclusion criteria 
• Exclusion criteria 
Collection of Data  : 
• Proforma 1  -  Informed Consent Form 
• Proforma 2  -  Patient details                      
• Proforma 3  -  Radiation therapy details 
• Proforma 4  -  Investigational parameters 
• Proforma 5  -  RTOG Radiation Morbidity Scoring 
• Proforma 6  - Adverse Events report form  
• Proforma 7  -  Patient education form 
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SITE OF THE STUDY 
 The study on “The Clinical comparison of the Efficacy of a herbal 
cream for the management of radio dermatitis in Cancer patients” was 
carried out in the Institute of Oncology in Kavery Medical Centre and 
Hospital located at Tiruchirappalli, from June 2011 to Feb 2012.  
 
DEPARTMENTS SELECTED FOR STUDY IN THE HOSPITAL: 
Patients selected for the study were both inpatients and 
outpatients from the Oncology Institute of the KMC hospital by getting 
consent from the Hospital Authority.  
 
CONSENT FORM THE HOSPITAL AUTHORITY 
 It is customary that every project work carried out in the hospital 
by the Department of Pharmacy Practice is informed to all the 
Physicians, Surgeons and other Healthcare Professionals of the 
hospitals after the approval from Ethics Committee. Henceforth, a 
protocol of the study, which includes the objectives, methodology, etc., 
was submitted to the Managing Director of the hospital.   
 The scholar was permitted to utilize the hospital facilities to 
make a follow up prescription, in the selected departments. All the 
health care professionals were well informed through the official 
circulars and patients were selected as per selection criteria and their 
consents were taken. 
 
 
 
 
 
Methodology  
 
116 
 
STUDY DESIGN 
 
Design of Data Entry Format [Proforma] 
 A separate data entry format [Proforma] for incorporating 
patient details was designed. The format contains details such as Name, 
Age, diagnosis, Past Medical History etc., The same is given in the 
appendix. 
Proforma- I: 
    Patient Informed Consent Form. 
Proforma- II: 
   Patient details - Name, Age, Sex, Address, Occupation, Social 
history, Diagnosis, Past medical history, Tumor differentiation.   
Proforma- III: 
  Radiotherapy details - Name of the patient, Treatment mode and 
site, Total targeted dose, Daily tumor dose, No of fractions, Treatment 
duration. 
Proforma- IV: 
 Investigational parameters - This includes the parameters and 
grading of skin complications according to the Radiation Therapy 
Oncology Group (RTOG) scale. 
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Proforma -V: 
WHO Skin assessment scale - This includes the scoring and 
toxicity grading for the assessment of skin complications. 
Proforma -VI: 
Adverse events assessment 
Proforma - VII: 
Patient education form - This includes 22 questionnaires that 
will be asked to the patient on their initial visit and during their 
radiotherapy treatment. Patient awareness will be created by 
means of a better patient education. 
 
TYPE OF RADIATION: 
 External radiation of tele - cobalt60. 
 
DOSE USED: 
 5000 – 6600 centigray 5 – 6 weeks at 5fractions per week.  
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PATIENT SELECTION: 
 
INCLUSION CRITERIA: 
 Subjects with histologic proof of Cervix, Breast, Head and neck, 
Lung and Pelvic malignances. 
 Be eligible to receive radiotherapy for atleast 5 Weeks duration. 
 Both genders 
 Age between 30 to 70 years 
 
EXCLUSION CRITERIA: 
 Pregnant or lactating women 
 Concurrent Use of Immunosuppressant 
 Active Infections Including Bacteria, Viral etc… 
 Patients with skin allergies/sensitized  skin 
 Patients with other co-morbities like 
 Inflammatory bowel disease 
 Nephrotic diseases 
 Hepatic diseases 
 Hematopoietic diseases etc… 
Project work methodology: 
1. 120 Patients were selected based on the inclusion - exclusion 
criteria in the Oncology department of the hospital. 
2. All the patients received 2 Gy/ fraction daily, for 5 weeks or 
more. 
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3. 60 Patients were treated with Amrad a herbal cream (Group 
A) to be applied in the morning and night time. They were 
asked to answer the questionnaire for evaluating the 
complications. 
4. 60 patients were treated as control Group (Group B) without 
the cream. 
5. The following parameters were measured: 
• The grading of complications of redness, hardness, dry 
desquamation, moist desquamation and atrophy of the 
skin has been evaluated from 1st week- 6th week by the 
scale RTOG (Radiation Therapy Oncology Group) in 
1995]. 
• The onset, severity and grading has been done daily 
for every fractions by the standard scale. 
6. Adverse events for both Group A and Group B patients were 
monitored   during the study by using standard Proforma. 
7.  Patient counseling was done at the entry of the study and at 
the end of the study. 
8. The whole procedure was carried out in cancer patients who 
were receiving radiotherapy treatment without any 
alteration therapy. 
Procedural details: 
 The drug for this study (Amrad cream) was given to the 
patient free of charge by us. 
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 This study was designed to find out the efficacy of Amrad 
Cream in prevention of radiation induced skin 
complications in radiation injured patients. 
 160 Radiation therapy undertaking patients who were 
scheduled to receive 2 Gy/day fraction of radiotherapy for 
5 weeks or more were selected on the basis of inclusion-
exclusion criteria.  
 The region planned for radiotherapy treatment was breast, 
cervix, oral, hypo pharynx, etc., 
 The total tumor dose planned for patients was 5040 cgy. 
 The approximate treatment duration was 5 weeks or more 
for each patient. 
 Radiation has been given for 28 fractions for all the 160 
patients.   
 The daily tumor dose was calculated to be 180 cgy for each 
patient. 
 All the patients were treated with EBRT (External Beam 
Radiotherapy )  
 Out of 120 patients, 60 patients were treated with Amrad 
cream (Group A, to be applied twice a day) and 60 
patients were treated as control Group (Group B). 
 Assessment of gastro intestinal complications was done 
weekly by using standard RTOG scale Proforma, the 
grading of skin complications were done by measuring 
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parameters such as Erythema, Epilation, Desquamation, 
Pain, Pigmentation changes, Edema, and Ulceration. 
 Adverse events for both the study Groups were measured 
during the radiotherapy treatment. 
 Patient education was also provided at the initial (base) 
level and the patient knowledge about cancers, 
radiotherapy treatment, skin problems, medication use 
and storage before and after patient education is assessed 
using patient education form. 
 
STATISTICAL ANALYSIS 
The values obtained were averaged for analysis. The collected 
data were analyzed by ANOVA test. 
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8. RESULTS 
Demographic data: 
Population: 
Out of 120 patients, 60 patients were belongs to Group A 
(Amrad group) and 60 patients were belongs to Group B (Untreated 
Control group). It is shown in (Figure 7 and Table 10). 
Gender: 
Among the demographic data collected for 120 patients,42 
patients (35%) were male and 78 patients (65%) were female, which 
confirms that women are more sensitive with Radiotherapy than men 
(Figure 8 and Table 11). 
Age: 
Out of the selected 120 patients, 2 patients (2%) were in the 
age Group of 20- 29 years, 12 patients (10%) were in the age Group 
of 30 – 39 years, 28  patients (23%) were in the age Group of 40 – 49 
years, 40 patients (59%) were in the age Group of 50 – 59 years, 34 
patients (28%) were in the age Group of 60-69 years and 4 patients 
(3%) were in the age Group of 70-79 . It indicates that more number 
of people in the age Group of 50-59 years is affected with 
Radiodermatitis (Figure 9 and Table 12) among the treated 
population. 
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Social habits of the patients: 
Out of the selected 120 patients, 27 patients (22%) were 
smokers,12 patients (10%) were tobacco users, 14 patients (12%) were 
alcoholics, 19 patients (16%) were betel  nut chewers, 11 patients (9%) 
were alcoholic and smokers, 4 patients (3%) were pan chewers, 33 
majority of the patients (28%) did not have any of these habits (Figure 
10 and Table 13). 
Type of cancer among the patients: 
Out of the 120 patients, the major diagnosis are cervical cancer – 
41 patients, breast cancer - 26 patients, hypo-pharynx - 5 patients, 
larynx - 6 patients,           oral cavity, oro pharynx, rectum, ovary each 
contains – 4 patients, esophagus – 9 patients, cheek – 3 patients, 
stomach, neck, lung each contains – 3 patients, lower lip, parotid, soft 
palate, sub mandible, tongue, penis, fore arm and sarcoma each 
contains-1 patient. It indicates that cervical cancer is one of the major 
types of cancer that affect most of the female patients (Figure 11 and 
Table 14). 
Tumour differentiation: 
 Out of 120 patients, the tumour differentiation was well in 48 
patients, moderate in 64 patients and poor in 8 patients. It indicates that 
moderately differentiated tumour is more than the other types (Figure 
12 and Table 15). 
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Amount of tumour dose used to the patients: 
 Among the 120 patients, in the radiation treatment the amount of 
tumour dose varies depend on the depth of the tumour, 40 gy of 
radiation was used to 11 patients, 50 gy was used for 72 patients, 60 gy 
was used for 19 patients, and 66 gy was used for 18 patients. Out of 
this, 50 gy of radiation was used to the maximum than the others 
(Figure 13 and Table 16). 
Type of Therapy: 
 Out of 120 patients, the type of the therapy was curative to107 
patients and it was palliative to 13 patients. It indicates that curative 
type of cancer is more likely than the palliative type (Figure 14 and 
Table 17). 
Type of treatment: 
 Out of 120 patients, the treatment varies to each other depending 
upon their stages of cancer, surgery and radiation was given to 38 
patients, chemotherapy and radiation was given to 19 patients and 
surgery, chemotherapy and radiation was given to 69 patients, the last 
treatment is preferred to the more number of patients (Figure 15 and 
Table 18). 
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Detection and diagnosis: 
 Out of 120 patients, the cancer is detected and diagnosed 
through varies detectors which mammogram was done to 22 patients, 
biopsy was done to 102 patients, fine needle aspiration was done by 39 
patients, CT scan was done by 23 patients, USG Abdomen/pelvis was 
done by 52 patients, endoscopy was done by 9 patients and chest X-ray 
was done by 6 patients. It indicates that biopsy was used to detect the 
cancer efficiently (Figure 16 and Table 19). 
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TABLE: 12 
AGE WISE DISTRIBUTION (N = 120) 
AGE NUMBER OF PATIENTS 
20-29 2 
30-39 12 
40-49 28 
50-59 40 
60-69 34 
70-79 4 
 
FIGURE: 9 
AGE WISE DISTRIBUTION (N=120) 
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TABLE: 14 
TYPE OF CANCER AMONG THE PATIENTS (N=120) 
TYPE OF CANCER 
NUMBER OF PATIENTS 
Total Male Female 
Breast 26 - 26 
Cervix 41 - 41 
Hypo Pharynx 5 4 1 
Larynx 6 6 - 
Oral cavity 4 3 1 
oropharynx 4 4 - 
Esophagus 9 9 - 
Lower lip 1 1 - 
Parotid 1 1 - 
Soft palate 1 1 - 
Sub mandible 1 1 - 
Tongue 1 1 - 
cheek 3 2 1 
Rectum 4 2 2 
Ovary 4 - 4 
Penis 1 1 - 
Stomach 2 2 - 
Neck 2 2 - 
Lung 2 1 1 
Fore arm 1 - 1 
sarcoma 1 1 - 
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TABLE: 15 
TUMOUR DIFFERENTIATION 
 
Tumour differentiation Number of Patients 
Well defined 48 
Moderate 64 
Poor 8 
 
FIGURE: 12 
TUMOUR DIFFERENTIATION 
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TABLE: 20 
MEAN SCORE FOR ERYTHEMA IN GROUP A AND  
GROUP B PATIENTS 
Patient ID Mean score for Group A Patient ID 
Mean score for 
Group B 
A1 0.82 B1 2.25 
A2 1.35 B2 2.17 
A3 1.14 B3 2.25 
A4 1.14 B4 2.92 
A5 0.82 B5 2.21 
A6 1.03 B6 2.28 
A7 1 B7 2.1 
A8 1.07 B8 2.07 
A9 1.25 B9 2.5 
A10 1.21 B10 2 
A11 1 B11 2.28 
A12 1.28 B12 3.5 
A13 1.17 B13 3 
A14 1 B14 3.89 
A15 1.62 B15 2.35 
A16 0.35 B16 2.17 
A17 1.74 B17 2.75 
A18 1.4 B18 2.92 
A19 0.92 B19 2.31 
A20 1.53 B20 2.28 
A21 1 B21 2.01 
A22 1.7 B22 2.07 
A23 1.75 B23 2.5 
A24 1.21 B24 1 
A25 1 B25 2.68 
A26 1.48 B26 3.5 
A27 1.97 B27 3 
A28 1 B28 3.39 
A29 0.24 B29 2.5 
A30 1.36 B30 2.7 
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A31 1.18 B31 2.50 
A32 1.14 B32 2.27 
A33 0.78 B33 2.41 
A34 1.34 B34 2.08 
A35 1 B35 2.1 
A36 1.87 B36 2.37 
A37 1.85 B37 2.1 
A38 1.01 B38 2 
A39 1 B39 2.58 
A40 1.58 B40 3.7 
A41 1.07 B41 3 
A42 1 B42 3.59 
A43 0.52 B43 2.65 
A44 1.45 B44 2.37 
A45 1.44 B45 2.75 
A46 1.74 B46 2.82 
A47 0.32 B47 2.61 
A48 1.83 B48 2.68 
A49 1 B49 2.1 
A50 1.97 B50 2.87 
A51 1.05 B51 2.9 
A52 1.21 B52 2 
A53 1 B53 2.28 
A54 1.48 B54 3.6 
A55 1.77 B55 3 
A56 1.42 B56 2.42 
A57 1 B57 2.18 
A58 1.52 B58 3.2 
A59 1 B59 3.23 
A60 0.83 B60 3.99 
TOTAL 63.08 TOTAL 129.09 
MEAN ± SD 0.1317 ± 0.2053 MEAN  ± SD 0.8371± 0.5597 
P Value highly significant*** <0.0001 
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TABLE: 21 
MEAN SCORE FOR EPILATION IN GROUP A AND 
 GROUP B PATIENTS 
Patient ID Mean score for Group A Patient ID 
Mean score for 
Group B 
A1 0.27 B1 0.46 
A2 0.29 B2 0.35 
A3 0.25 B3 0.43 
A4 0.45 B4 0.45 
A5 0.56 B5 0.65 
A6 0.5 B6 0.36 
A7 0.25 B7 0.23 
A8 0.5 B8 0.24 
A9 0.5 B9 0.22 
A10 0.25 B10 0.26 
A11 0.42 B11 0.15 
A12 0.45 B12 0.28 
A13 0.45 B13 0.25 
A14 0.65 B14 0.26 
A15 0.35 B15 0.25 
A16 0.37 B16 0.42 
A17 0.16 B17 0.5 
A18 0.23 B18 0.82 
A19 0.24 B19 0.84 
A20 0.22 B20 1 
A21 0.12 B21 0.5 
A22 1 B22 0.5 
A23 0.23 B23 0.5 
A24 0.44 B24 0.55 
A25 0.43 B25 0.65 
A26 0.27 B26 0.66 
A27 0.34 B27 0.68 
A28 0.45 B28 0.25 
A29 0.43 B29 0.54 
A30 0.42 B30 0.48 
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A31 0.5 B31 0.44 
A32 0.82 B32 1 
A33 0.84 B33 1 
A34 1 B34 1 
A35 0.5 B35 1 
A36 0.5 B36 1 
A37 0.5 B37 1 
A38 0.55 B38 1 
A39 0.65 B39 1 
A40 0.66 B40 1 
A41 0.68 B41 1 
A42 0.25 B42 1 
A43 0.54 B43 1 
A44 0.48 B44 1 
A45 0.44 B45 1 
A46 0.46 B46 0.27 
A47 0.35 B47 0.29 
A48 0.43 B48 0.25 
A49 0.45 B49 0.45 
A50 0.65 B50 0.56 
A51 0.36 B51 0.5 
A52 0.23 B52 0.25 
A53 0.24 B53 0.5 
A54 0.22 B54 0.5 
A55 0.26 B55 0.25 
A56 0.15 B56 0.42 
A57 0.28 B57 0.45 
A58 0.25 B58 0.45 
A59 0.26 B59 0.65 
A60 0.25 B60 0.35 
TOTAL 25.24 TOTAL 34.31 
MEAN ± SD 0.4206±0.1936 MEAN ± SD 0.5718±0.2871 
 
P Value highly significant*** <0.0001 
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TABLE: 22 
MEAN SCORE FOR OEDEMA IN GROUP A AND  
GROUP B PATIENTS 
Patient ID 
Mean score for 
group A Patient ID 
Mean score for 
group B 
A1 0 B1 0 
A2 0 B2 1 
A3 0 B3 0 
A4 0 B4 0 
A5 0 B5 0 
A6 0 B6 1.6 
A7 0 B7 0 
A8 0 B8 0 
A9 0.11 B9 0 
A10 0 B10 0 
A11 0 B11 0 
A12 0 B12 0 
A13 0.17 B13 1.5 
A14 0 B14 0 
A15 0 B15 0 
A16 0 B16 0 
A17 0 B17 1 
A18 0 B18 0 
A19 0 B19 0 
A20 0 B20 0 
A21 0 B21 1.65 
A22 0.14 B22 0 
A23 0 B23 0 
A24 0 B24 0 
A25 0 B25 1 
A26 0 B26 0 
A27 0 B27 0 
A28 0 B28 0 
A29 0 B29 0 
A30 0 B30 1.8 
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A31 0 B31 0 
A32 0 B32 0 
A33 0.3 B33 0 
A34 0 B34 0 
A35 0 B35 0 
A36 0 B36 0 
A37 0 B37 0 
A38 0 B38 1 
A39 0 B39 0 
A40 0 B40 0 
A41 0 B41 0 
A42 0.11 B42 0 
A43 0 B43 0 
A44 0 B44 0 
A45 0 B45 0 
A46 0 B46 1 
A47 0 B47 0 
A48 0 B48 0 
A49 0 B49 0 
A50 0.16 B50 0 
A51 0 B51 0 
A52 0 B52 0 
A53 0 B53 0 
A54 0 B54 0 
A55 0 B55 0 
A56 0 B56 0 
A57 0 B57 1.75 
A58 0 B58 0 
A59 0 B59 0 
A60 0 B60 0 
TOTAL 0.99 TOTAL 13.3 
MEAN±SD 0.0804±0.0333 MEAN±SD 0.0983±0.2808 
P Value highly significant*** <0.0001 
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TABLE: 23 
MEAN SCORE FOR PAIN IN GROUP A AND GROUP B PATIENTS 
Patient ID Mean score for group A Patient ID 
Mean score for 
group B 
    
A1 0.25 B1 1 
A2 0.25 B2 1 
A3 0.19 B3 1 
A4 0.2 B4 0 
A5 0 B5 1.5 
A6 0 B6 1.39 
A7 0 B7 1.25 
A8 0 B8 0 
A9 0.34 B9 0 
A10 0.45 B10 1 
A11 0.42 B11 0 
A12 0 B12 0 
A13 0.5 B13 0 
A14 0.33 B14 0 
A15 0.15 B15 1.2 
A16 0 B16 1.5 
A17 0 B17 0 
A18 0.12 B18 0 
A19 0.5 B19 0 
A20 0.42 B20 0 
A21 0.24 B21 1 
A22 0.55 B22 0 
A23 0 B23 0 
A24 0 B24 0 
A25 0 B25 1.6 
A26 0 B26 0 
A27 1 B27 0 
A28 0 B28 0 
A29 0 B29 1 
A30 0 B30 0 
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A31 0 B31 0 
A32 0.2 B32 0 
A33 1.5 B33 0 
A34 1.34 B34 1.9 
A35 1.5 B35 1.67 
A36 1 B36 0 
A37 1 B37 1.45 
A38 0 B38 1.55 
A39 0 B39 1 
A40 0 B40 0 
A41 0 B41 0 
A42 0 B42 0 
A43 0.15 B43 1 
A44 0.13 B44 0 
A45 0.24 B45 0 
A46 1 B46 0 
A47 0.31 B47 2 
A48 0.34 B48 2.1 
A49 0.2 B49 1.72 
A50 0 B50 0 
A51 0 B51 0 
A52 0 B52 1 
A53 1 B53 0 
A54 0 B54 0 
A55 0 B55 0 
A56 0.62 B56 0 
A57 1 B57 1 
A58 1.5 B58 1 
A59 0 B59 1 
A60 0.25 B60 1 
TOTAL 19.19 TOTAL 33.83 
MEAN±SD 0.3198±0.4341 MEAN±SD 0.5638±0.6912 
P Value highly significant*** <0.0001 
 
 
 
 
 D
w
m
B
is
 
esquamat
The t
as less th
uch less i
oth group
 shown in
MEAN
ion: 
otal score
an that of 
n Group A
s show sta
 Figure 21 
FIG
 SCORE F
GROUP
7
 for desqu
Group B 
 0.12 ± 0.2
tistically si
and Table 
URE 21: 
OR DESQ
GROUP
 A
.37
 
 
 
149
amatiom 
(22.09). Th
9 as comp
gnificant d
24. 
 
DESQUAM
UAMATI
 B PATIE
 
 
GRO
 for Group
e mean sc
ared to G
ifference b
ATION 
ON IN GR
NTS 
UP B
22.09
 A patien
ore is foun
roup B 0.3
y student
OUP A A
GRO
GRO
Results  
ts (7.37) 
d to be 
6 ± 0.50. 
 t test. It 
ND  
 
UP A
UP B
 
 
 
Results  
 
150 
 
TABLE: 24 
MEAN SCORE FOR DESQUAMATION IN GROUP A AND  
GROUP B PATIENTS 
 
Patient ID Mean score for group A Patient ID 
Mean score for 
group B 
A1 0.23 B1 1 
A2 0.21 B2 1 
A3 0 B3 0.5 
A4 0 B4 1 
A5 1.5 B5 0 
A6 1.2 B6 0 
A7 0 B7 1.65 
A8 0 B8 0 
A9 0 B9 0 
A10 0.15 B10 0 
A11 0.2 B11 1.25 
A12 0.5 B12 0 
A13 0.25 B13 0 
A14 0 B14 0 
A15 0 B15 1 
A16 0 B16 0.23 
A17 0 B17 0 
A18 0 B18 0 
A19 0 B19 0 
A20 0 B20 0 
A21 0 B21 0 
A22 0 B22 0 
A23 0 B23 1.5 
A24 0 B24 0 
A25 0 B25 0 
A26 0 B26 0 
A27 0 B27 0 
A28 0 B28 0 
A29 0 B29 1 
A30 0 B30 1 
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A31 1 B31 1 
A32 0 B32 0 
A33 0 B33 0 
A34 0 B34 0 
A35 0 B35 0 
A36 0 B36 0 
A37 0 B37 0 
A38 0 B38 0.65 
A39 0 B39 0 
A40 0 B40 1 
A41 0 B41 1 
A42 0.45 B42 1 
A43 0.3 B43 0 
A44 0.46 B44 0 
A45 0 B45 0 
A46 0 B46 0.82 
A47 0 B47 0.54 
A48 0.62 B48 1 
A49 0 B49 1 
A50 0 B50 1 
A51 0 B51 0 
A52 0 B52 0 
A53 0.3 B53 0 
A54 0 B54 0 
A55 0 B55 0.95 
A56 0 B56 0 
A57 0 B57 0 
A58 0 B58 0 
A59 0 B59 0 
A60 0 B60 1 
TOTAL 7.37 TOTAL 22.09 
MEAN±SD 0.1228±0.2978 MEAN±SD 0.3681±0.5041 
P Value highly significant*** <0.0001 
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TABLE: 25 
MEAN SCORE FOR PIGMENTATION CHANGES IN GROUP A 
AND GROUP B PATIENTS 
Patient ID Mean score for Group A Patient ID 
Mean score for 
Group B 
A1 0.5 B1 0.12 
A2 0.12 B2 0.2 
A3 0.25 B3 0.1 
A4 0.5 B4 1 
A5 1 B5 1 
A6 1 B6 1 
A7 0 B7 1 
A8 1 B8 0.5 
A9 0.65 B9 1 
A10 0.45 B10 0 
A11 0 B11 1 
A12 0 B12 1 
A13 0 B13 0.2 
A14 0 B14 0.15 
A15 1 B15 0.12 
A16 1 B16 0.1 
A17 1 B17 0.3 
A18 1 B18 0.23 
A19 1 B19 0 
A20 0.2 B20 1 
A21 0.23 B21 1 
A22 0.26 B22 1 
A23 0.24 B23 1 
A24 0.14 B24 1 
A25 0.5 B25 1 
A26 0.8 B26 0.2 
A27 0.54 B27 0.1 
A28 0 B28 0.32 
A29 0 B29 0.22 
A30 0 B30 0.1 
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A31 0 B31 0.2 
A32 1 B32 0.5 
A33 0 B33 1 
A34 0 B34 1 
A35 0 B35 0.55 
A36 0 B36 0.6 
A37 0 B37 1 
A38 0 B38 1 
A39 0 B39 0.3 
A40 0 B40 1 
A41 0 B41 0 
A42 0 B42 0 
A43 0 B43 1.45 
A44 1 B44 1 
A45 0 B45 1 
A46 0 B46 0 
A47 0 B47 1 
A48 0 B48 0.54 
A49 0 B49 0.65 
A50 0 B50 0.23 
A51 0 B51 0.43 
A52 0 B52 0.56 
A53 0.23 B53 1.9 
A54 0 B54 0 
A55 0 B55 1 
A56 0 B56 2 
A57 0.25 B57 1 
A58 0 B58 1 
A59 0 B59 1 
A60 0 B60 1 
TOTAL 32.295 TOTAL 39.54 
MEAN ± SD 0.5382±0.4295 MEAN ± SD 0.659±0.4125 
P Value highly significant*** <0.0001 
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TABLE: 26 
MEAN SCORE FOR TELANGIECTASIA IN GROUP A AND 
GROUP B PATIENTS 
Patient ID Mean score for Group A Patient ID 
Mean score for 
Group B 
A1 0 B1 1 
A2 0 B2 1 
A3 0 B3 1 
A4 0.3 B4 1 
A5 0 B5 1 
A6 0 B6 0.24 
A7 0 B7 0.2 
A8 0 B8 0.5 
A9 0.23 B9 0.66 
A10 0 B10 0.54 
A11 0 B11 1 
A12 0 B12 1.23 
A13 0 B13 1 
A14 0 B14 0 
A15 1 B15 0 
A16 0 B16 0 
A17 0 B17 1.65 
A18 0 B18 1 
A19 0 B19 0 
A20 0 B20 0 
A21 0 B21 0.54 
A22 0.12 B22 0.34 
A23 0.14 B23 1 
A24 0.124 B24 0 
A25 0 B25 0 
A26 0 B26 1.9 
A27 0 B27 0.2 
A28 0 B28 0.24 
A29 0 B29 0 
A30 0 B30 0.27 
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A31 0 B31 0.2 
A32 1 B32 0.5 
A33 0 B33 1 
A34 0 B34 1 
A35 0 B35 0.55 
A36 0 B36 0.6 
A37 0 B37 1 
A38 0 B38 1 
A39 0 B39 0.3 
A40 0 B40 1 
A41 0 B41 0 
A42 0 B42 0 
A43 0 B43 1.45 
A44 1 B44 1 
A45 0 B45 1 
A46 0 B46 0 
A47 0 B47 1 
A48 0 B48 0.54 
A49 0 B49 0.65 
A50 0 B50 0.23 
A51 0 B51 0.43 
A52 0 B52 0.56 
A53 0.23 B53 1.9 
A54 0 B54 0 
A55 0 B55 1 
A56 0 B56 2 
A57 0.25 B57 1 
A58 0 B58 1 
A59 0 B59 1 
A60 0 B60 1 
TOTAL 4.394 TOTAL 40.42 
MEAN ± SD 0.0732±0.2249 MEAN ± SD 0.6736±0.5254 
P Value highly significant*** <0.0001 
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TABLE: 27 
MEAN SCORE FOR ULCERATION IN GROUP A AND  
GROUP B PATIENTS 
Patient ID 
Mean score for 
group A Patient ID 
Mean score for 
group B 
A1 0 B1 1 
A2 0 B2 1 
A3 0 B3 1 
A4 0 B4 1 
A5 0 B5 0 
A6 0 B6 0 
A7 0.1 B7 0 
A8 0.09 B8 0 
A9 0 B9 0 
A10 0 B10 0 
A11 0 B11 0.25 
A12 0 B12 0 
A13 0 B13 0 
A14 0 B14 0 
A15 0.1 B15 0 
A16 0.085 B16 1 
A17 0 B17 0 
A18 0 B18 0 
A19 0 B19 0 
A20 0 B20 1 
A21 0 B21 1 
A22 0 B22 1 
A23 0.09 B23 1 
A24 0 B24 1 
A25 0 B25 0 
A26 0 B26 0 
A27 0 B27 0 
A28 0 B28 0 
A29 0 B29 1.5 
A30 0 B30 1 
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A31 0 B31 1 
A32 0.16 B32 1.05 
A33 0 B33 1 
A34 0 B34 1 
A35 0 B35 1 
A36 0 B36 1 
A37 0 B37 1 
A38 0 B38 1 
A39 0 B39 0.6 
A40 0 B40 1 
A41 0 B41 1 
A42 0 B42 0 
A43 0.15 B43 0 
A44 0 B44 0 
A45 0 B45 0 
A46 0 B46 0 
A47 0 B47 0 
A48 0 B48 1 
A49 0 B49 1 
A50 0 B50 1 
A51 0 B51 1 
A52 0 B52 2.1 
A53 0 B53 0 
A54 0.54 B54 0 
A55 0 B55 0 
A56 0 B56 1.2 
A57 0 B57 1 
A58 0 B58 1 
A59 0 B59 1 
A60 0.14 B60 1 
TOTAL 1.455 TOTAL 34.7 
MEAN±SD 0.0242±.0789 MEAN±SD 0.5783±0.5455 
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Cumulative score analysis: 
Table 28, Figure 25 & 26 shows the overall toxicity scores of all 
the parameters among Group A (Amrad cream) and Group B 
(Untreated Control).The mean and standard deviation of both the 
group were found to be 6.85 ± 2.6877 and 14.76 ± 4.1451 respectively. 
Both groups show statistically significant difference by student t test. 
The mean of toxicity evaluation grading for Group A (Amrad) 
and Group B (Control) were found to be 0.88 and 2.25 respectively. This 
shows that the drug is more effective than control. 
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TABLE: 28 
OVERALL MEAN TOXICITY SCORE FOR SKIN REACTIONS 
Patient 
ID 
Total score of all  
the parameters 
(group A) 
Toxicity 
evaluation 
grading 
Patient 
ID 
Total score of  all 
the parameters 
(group B) 
Toxicity 
evaluation 
grading 
A1 2.8 1 B1 11.4 2 
A2 2.5 1 B2 10.6 2 
A3 9.72 1 B3 13.6 2 
A4 8.28 1 B4 17.78 2 
A5 9.37 1 B5 12.76 2 
A6 7.36 1 B6 13.5 2 
A7 7.87 1 B7 10.9 2 
A8 7.43 1 B8 9.8 2 
A9 5.34 1 B9 8.75 1 
A10 1.96 0 B10 15.4 2 
A11 3.56 1 B11 14.7 2 
A12 4.43 1 B12 15.8 2 
A13 4.87 1 B13 18.6 3 
A14 6.34 1 B14 16.76 2 
A15 5.43 1 B15 15.89 2 
A16 6.23 1 B16 9.16 2 
A17 7.54 1 B17 14.56 2 
A18 9.5 1 B18 18 2 
A19 1.65 0 B19 11.5 2 
A20 4.15 1 B20 10.66 2 
A21 7.28 1 B21 11.54 2 
A22 9.7 1 B22 13 2 
A23 6.91 1 B23 16.7 2 
A24 9.5 1 B24 8.8 1 
A25 5.55 1 B25 14.3 2 
A26 7.5 1 B26 12.2 2 
A27 0.96 0 B27 14.5 2 
A28 4.98 1 B28 15.24 2 
A29 5.2 1 B29 16.65 2 
A30 9.26 1 B30 11.55 2 
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A31 9.35 1 B31 18.5 3 
A32 7.68 1 B32 19.55 3 
A33 6.87 1 B33 18.77 3 
A34 1.55 0 B34 20.55 3 
A35 9.98 1 B35 19.55 3 
A36 9.32 1 B36 18.6 3 
A37 7.97 1 B37 9.56 2 
A38 9.55 1 B38 9.2 2 
A39 1.66 0 B39 10.66 2 
A40 8.08 1 B40 12.66 2 
A41 10.7 1 B41 15.5 2 
A42 8 1 B42 6.55 1 
A43 7.59 1 B43 21.5 3 
A44 8.1 1 B44 22.1 3 
A45 6.37 1 B45 18.7 3 
A46 18.5 3 B46 11.6 2 
A47 19.55 3 B47 10.98 2 
A48 18.77 3 B48 9.8 2 
A49 20.55 3 B49 9.86 2 
A50 19.55 3 B50 10.5 2 
A51 18.6 3 B51 11.23 2 
A52 9.56 2 B52 14.56 2 
A53 9.2 2 B53 20.5 3 
A54 10.66 2 B54 19.8 3 
A55 12.66 2 B55 21.9 3 
A56 15.5 2 B56 19.25 3 
A57 6.55 1 B57 18.55 3 
A58 21.5 3 B58 19.56 3 
A59 22.1 3 B59 21.55 3 
A60 18.7 3 B60 19.88 3 
MEAN ±SD 6.85±2.6877 0.88 MEAN±SD 14.76±4.1451 2.25 
 
P value - < 0.0001            *** Very highly Significant by Student T Test 
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Radiation-Induced Acute Skin Reactions Evaluated with  
RTOG Scale: 
Table 29 shows that in Group A, the number of patients in Grade 
0, 1, 2, 3, 4 were 7(12%), 53(88%), 0, 0, 0 respectively. In Group B, the 
number of patients in Grade 0, 1, 2, 3, 4 were 0, 3(5%), 39(65%), 18(30%), 
0 respectively. This result shows that about 30% of the patients in 
control had toxicity grade 3 whereas in group treated with Amrad 
cream has the toxicity scores only in grade 0 and 1. 
 
 Table 29: Toxicity grading for skin reactions  
TOXICITY  
GRADING 
 
GROUP A GROUP B 
No. of 
patients % of patients 
No. of 
patients 
% of 
patients 
GRADE 0 7 12 0 0 
GRADE 1 53 88 3 5 
GRADE 2 0 0 39 65 
GRADE 3 0 0 18 30 
GRADE 4 0 0 0 0 
 
 
 
 
 
 
Results  
 
166 
 
Adverse events:             
Figure 27 and Table 30 show the presence of adverse events in 
Group A and Group B patients. The adverse events analysis reveals 
that in Group A, 36% of patients had RT pain, 18% of patients had 
nausea, 16% of patients had vomitting, 27% of patients had mouth 
dryness, 18% of patients had constipation, 27% of patients had 
dysphagia, 26% of patients had giddiness and 62% of patients had 
mucositis. In Group B, 40% of patients had RT pain, 33% of patients 
had nausea, 26% of patients had vomitting, 33% of patients had mouth 
dryness, 20% of patients had constipation, 26% of patients had 
dysphagia, 33% of patients had giddiness and 67% of patients had 
mucositis. 
Table: 30 
ADVERSE DRUG EVENTS FOR GROUP A (AMRAD CREAM) 
AND GROUP B (CONTROL) 
 
ADVERSE DRUG 
REACTION 
GROUP A GROUP B 
RT PAIN 36% 40% 
NAUSEA 18% 33% 
VOMITTING 16% 26% 
DRYNESS OF 
MOUTH 
27% 33% 
CONSTIPATION 18% 20% 
DYSPHAGIA 27% 26% 
GIDDINESS 26% 33% 
MUCOSITIS 62% 67% 
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Figure 27 
 
ADVERSE DRUG EVENTS FOR GROUP A (AMRAD CREAM) 
AND GROUP B (CONTROL) 
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Patient education: 
Table 31 indicates the impact of patient education (counseling) of 
patient knowledge about cancer, radiotherapy treatment side effects, 
treatment of radiation induced skin complications, medication usage 
and storage and dietary counseling. It clearly indicates that patient 
knowledge of the above mentioned factors have been improved after 
patient education (counseling). It shows the importance of patient 
counseling to improve the therapeutic outcomes and quality of life of 
the patients. Further it confirms that patient counseling can improve 
the patient compliance and adherence to therapy. 
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Table : 31 
PATIENT EDUCATION FORM 
 
Questions 
Before 
patient 
education 
After patient 
education 
Percentage of 
improved 
patient 
knowledge 
1) Do you know about cancer? 
            a) Yes     
            b) No 
If yes, what do you know about 
cancer? 
            a) Malignant tumor    
            b) Benign tumor  
            c) Malignant tumor and  
                Metastasis   
            d)  Others 
 
99 (82%) 
21 (18%) 
 
 
44 (45%) 
21 (22%) 
23 (24%) 
9 (9%) 
 
120 (100%) 
 
 
 
 
 
11 (9%) 
109 (91%) 
 
100% 
 
 
 
 
89% 
2) What are the social habits that 
cause cancers? 
           a) Tobacco use      
           b) Betel nut use   
           c) Alcohol use       
           d) Smoking           
           e) All  
 
 
12 (12%) 
19(18%) 
14(13%) 
27(26%) 
33(31%) 
 
 
 
 
 
12 (10%) 
108(90%) 
97% 
3) Do you have any of these 
social habits? 
            a) Yes   
            b) No  
 
 
87 (72%) 
33 (28%) 
 
 
9 (7%) 
111 (93%) 
 
 
92.5% 
 
4) What are the treatments 
available for cancers? 
           a)  Radiotherapy   
           b) Chemotherapy 
           c)  Surgery 
           d) Combination of any of    
               the above (a/b/c) 
 
 
 
52 (43%) 
28 (23%) 
33 (28%) 
7 (6%) 
 
 
 
 
120 (100%) 
 
 
 
 
100% 
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5) Do you know about the 
Radiotherapy treatment? 
            a) Yes 
            b) No 
 
 
 
92 (77%) 
28 (23%) 
 
 
120 (100%) 
 
 
100 % 
6)     Do you know that you have 
to attend the radiotherapy 
regularly as per doctor’s advice? 
             a) Yes  
             b) No 
 
 
 
102 (85%) 
18 (15%) 
 
 
 
120 (100%) 
 
 
 
100% 
7) Do you know that radiotherapy 
interruption would delay up the 
effectiveness of your treatment? 
          a) Yes  
          b) No 
 
 
 
 
44 (37%) 
76 (63%) 
 
 
 
 
120 (100%) 
 
 
100% 
8) Are you aware of the side   
effects of the Radiotherapy 
treatment? 
           a) Yes  
           b) No 
If yes, who told you? 
           a) Doctor                                  
           b) Pharmacist 
           c) Nurse 
           d) Others 
   
 
 
 
22 (18%) 
98 (82%) 
 
13 (59%) 
9 (41%) 
        
 
 
     109 (91%) 
       11(9%) 
 
 
- 
 
 
 
          91% 
9) Do you know that Radio 
dermatitis one of the side effects 
of the radiotherapy treatment? 
            a) Yes  
            b) No 
        
 
 
       23 (19%) 
       97 (81%) 
 
 
120 (100%) 
 
 
100% 
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10) How will you manage the 
Radio dermatitis? 
 a)  By applying oil. 
 b)  By applying Amrad cream. 
 c)  By informing doctor                 
 d)  None 
 
 
44 (37%) 
12(10%) 
47(39%) 
17(14%) 
 
 
21 (17%) 
67(56%) 
32 (27%) 
- 
 
 
 
NA 
 
 11)  Do you have any problems 
with the Amrad cream? 
             a) Yes 
             b)  No 
 
 
 
7 (12%) 
52 (88%) 
 
 
60 (100%) 
 
 
100% 
12) Where do you store your 
medicine? 
             a) Refrigerator           
             b) At room temperature   
             c) Others 
     
     54 (90%) 
       6 (10%) 
 
60 (100%) 
 
100% 
13) Do you know how to use this 
medicine? 
             a) Yes  
             b) No 
 
 
56 (93%) 
4 (7%) 
 
 
60 (100%) 
 
 
100% 
14) Do you know when to apply 
this medication? 
             a) Morning and night  
             b) Night 
             c) Evening 
             d) At any time 
 
 
     21 (33%) 
     19 (30%) 
       0  
     23 (37%) 
 
 
 
60 (100%) 
 
 
100 % 
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15) If you find any side effects 
while taking the medication 
what will you do? 
  a) I will inform to the doctor  
  b) I will skip the  medication 
  c) I don’t know 
  d ) I will chose alternative   
        myself  
 
 
 
37 (72%) 
9 (18%) 
3 (6%) 
2 (4%) 
 
 
 
57 (95%) 
3 (5%) 
 
 
 
89% 
16)  Do you have faith that your 
treatment would cure   the 
disease? 
           a) Yes I have faith  
           b)  No I don’t have 
 
 
71 (59%) 
49 (41%) 
 
 
111 (92%) 
9(8%) 
 
 
92.5% 
17)  Are you following the 
doctor’s advice? 
           a) Yes  
           b) No 
 
 
87 (72%) 
33(28%) 
 
 
120 (100%) 
 
 
100% 
18) Are you following the 
dietary instructions such as 
taking rich fruit juices, soft foods 
and avoiding hot spicy foods 
properly? 
            a) Yes  
            b) No 
 
 
 
 
69 (57%) 
51 (43%) 
 
 
120 (100%) 
 
 
100% 
19) Are you applying the 
Medication regularly? 
           a)  Yes  
           b)  No 
 
52 (87%) 
8 (13%) 
 
60 (100%) 
 
100% 
20) Do you check the expiry date 
while purchasing the 
medication?  
            a) Yes 
            b) No 
 
 
57(95%) 
3(5%) 
 
60 (100%) 
 
100% 
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21) Do you think that the benefit 
supersede the cost of the 
treatment? 
           a) Yes 
           b) No 
 
 
 
      51 (88%) 
         7(12%) 
 
 
- 
 
 
NA 
22) Do you know that there is 
greater chance of recurrence of 
cancers and that regular follow-
up visit is vital 
          a) Yes  
          b) No 
 
 
 
 
67 (56%) 
53 (44%) 
 
 
 
 
120 (100%) 
 
 
 
 
100% 
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9. DISCUSSION 
 
The demographics in this study reveal that the risk of developing 
cancer increases with age. The results show that 59% of patients were in 
the age group between 50 - 59 who were affected with radiodermatitis. 
Further in the population under study, 65% were female and 35% were 
male. This clearly shows that predominantly women get affected more 
than men. 
 
In most cases the cause of cancer is multifactorial. About 75% of 
cancers are due to environmental factors and some are due to 
individuals, e.g tobacco chewing, smoking etc (Bennett P.N et al., 
1996).  
 
Among the 120 patients entered into the study, 41 patients were 
found to be affected with cervical carcinoma. According to this report, 
most of the women were diagnosed with cervical cancer comparing to 
other cancers. Patients involved in this study group were mostly with 
curative moderately differentiated tumours and the amount of tumour 
dose used was 50gy. 
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The comparative data’s in this study reveals that there is a 
remarkable changes in the radiation-induced skin complications such 
as erythema, Epilation, edema, pain, desquamation, pigmentation 
changes, telangiectasia and ulceration. This study paves a way to 
decrease the rate of skin complications by applying the herbal cream 
Amrad.  
 
¾ Erythema: 
The comparative data shows that the herbal cream has reduced 
the erythematic condition of the patients in Group A (Amrad 
treated group) than the patients in Group B (untreated control 
group). Erythema is caused due to the release of cytokines that 
leads to leukocyte infiltration and localized swelling. 
¾ Epilation: 
Aloe vera is used to treat epilation conditions (Zawahry M. et 
al., 1973). It is reported that the “complete regeneration of skin of 
the forehead and scalp, new hair growth, complete restoration of 
sensation, and absence of scars (C. E. and Creston Collinset al., 
1935). It reduces the condition of epilation which is caused due to 
the damage of sebaceous glands and hair follicles in the dermal 
layer. This clearly reveals that the skin toxicity is less in group of 
patients treated with Amrad cream. 
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¾ Pain: 
Radiotherapy induced pain occurred in most of the cancer 
patients during their treatment period (Robert H. Davis et al., in 
1988). The results show that the severity of pain in Group A 
patients is less than that of Group B. 
¾ Edema: 
Edema which is characterized by the accumulation of the 
excessive watery fluids in the cells/tissues is also one of the skin 
complications during radiation therapy (J.E. (MD) et al., 1937). 
In this study, the patients in group A had decreased condition of 
edema than the Group B. 
¾ Desquamation: 
The condition of desquamation characterized by dryness, scaling 
and purities (Cole et al., in 1935) has been reduced in group A 
patients than the patients in group B. 
¾ Pigmentaton changes: 
 Pigmentaton changes due to the destroyed dermal melanocyte is 
seen to be reduced in the group A patients than the patients in 
group B. 
¾ Telangiectasia: 
Telangiectasia characterized by the prominent, dilated, thin 
blood vessels (Carroll. S .Wright M.D et al., in 1936) has been 
reduced in the group A patients than the patients in group B. 
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¾ Ulceration: 
C. C. Lushbaugh M.D et al., in 1953 concluded in his study that 
A. Vera contains substances that are stimulatory both to the 
relayed development and delayed healing of ulcerative radio 
dermatitis. Ulceration  has been reduced in the group A patients 
than the patients in group B. 
¾ Cumulative score: 
The mean and standard deviation for the overall score for all the 
parameters among Group A (Amrad) were compared with that 
of Group B (Control) and it is calculated .The toxicity evaluation 
grading shows that there is a remarkable decline in the severity 
of symptoms in the treated group (Group A) when compared to 
control group (Group B). The mean toxicity grade is higher in 
Group B than Group A. 
No grade 2 or 3 maximum is seen in the group A. Thus the 
treated group (Group A) is showing a good protection against 
radiation induced skin complications than the control group 
(Group B). 
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ADR 
The presence of adverse events in Group A and Group B patients 
was studies. The adverse events were analyzed for  RT pain, nausea, 
vomiting, mouth dryness, constipation, dysphagia, giddiness. The data 
shows a protective effect was seen in the Amrad group than the control 
group. 
 
PATIENT EDUCATION 
The impact of patient education (counseling) had shown 
significant improvement on patient knowledge about cancer, 
radiotherapy treatment side effects, treatment of gastro intestinal 
complications, medication usage and storage; and dietary counseling. 
The added advantage of the counseling was perhaps due to the fact 
that it was made in local vernacular. 
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CONCLUSION 
 
This study concludes thus: 
 
 Age group of 50-59 is highly at risk for cancer. 
 Females are affected more than males. 
 Smoking and tobacco chewing are the definitive risk factors. 
 Cervix and breast cancer are the most prevalent types in women and 
oesophagus and larynx in men. 
 Most of the tumours are moderately differentiated. 
 All cumulative scores for skin reaction parameters clearly reveal 
that there is a desirable effect produced by Amrad cream in group A 
as compared to group B. 
 The final conclusion of the toxicity study shows that radiation 
induced acute skin reactions of grade 2 and grade 3 are seen in the 
control group whereas the Amrad treated group does not show the 
toxicity of grade 2 or  above. 
 The ADR effects are found to be mild in the herbal cream group A 
compared to the control group B. 
 Patient counseling has improved the patient’s knowledge about 
cancer and radio dermatitis problems, its drug usage and the patient 
compliance. 
 
Hence we conclude that Amrad is safe and effective in reducing 
the incidence of radio dermatitis in cancer patients undergoing 
radiotherapy and also it reduces the severity of grade 2 toxicity in these 
patients. 
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 PROFORMA – I 
 
INFORMED CONSENT FORM 
 
Patient Name:                                           Date: 
Age:                                                              Sex: 
     I was explained about the description of the research study and 
they have answered all the questions I have at this time. 
       I freely volunteer to participate in this study. I understand that I 
need not have to take part in this study and that my refusal to 
participate will involve no penalty. Further I understand that I am free 
to discontinue participation from this study at any time. 
                    
Clinician’s Name:         Patient’s name: 
                                                                         
                                                                    Signature: 
 
 
 
 
PROFORMA – II 
PATIENT DETAILS FORM 
 
Patient’s Name :                                                   RT NO :                                
Age   :                                                   TR NO : 
Sex   :                                                  HR NO :   
Address  :  
Ph.No  : 
Weight  : 
Height  : 
Occupation  :                                     
Date of  first consultation :                           
Reason for Admission  :    
Social History   :     a)Smoker   b)Alcoholic c)Vegetarian     
           d)Non vegetarian e)Tobacco f)None 
Past Medical History  :        
Diagnosis    :                                              
Surgery/ Radiation  :               
History of present illness :               
 
 
 
PROFORMA – III 
RADIATION (RT) DETAILS 
Patient name     :                                              
Radiotherapy type    : Teletherapy  
Site treated       :  
Total tumor dose prescribed   :                    
Treatment duration    :                                          
Total no. of fractions prescribed  :                       
Daily tumor dose     : 
 
RADIATION CHART 
Radiation 
Date 
Day 
Daily 
surface 
dose (Gy) 
Total 
surface 
dose (Gy) 
Daily 
tumour 
dose (Gy) 
Total 
tumour 
dose (Gy) 
      
      
      
      
      
 
 
PROFORMA – IV 
INVESTIGATIONAL PARAMETERS 
Review Erythema Epilation Edema Desquamation 
Pigmentation 
changes 
Telangiectasis Pain Ulceration 
         
         
         
         
 
 
    
PROFORMA- V 
 
WHO SKIN TOXICITY ASSESSMENT SCALE 
 
 
WHO TOXICITY  ASSESSMENT SCALE 
TOTAL  SCORE 
TOXICITY  EVALUATION  
GRADINGS 
0-2 0 
3-9 1 
10-18 2 
19-27 3 
28-36 4 
 
 
 
 
 
 
 
 
PROFORMA-VI 
 
ADVERSE DRUG EFFECTS FORM 
 
Weeks Pain Nausea Itching Mouth 
Dryness 
Dysphagia Giddiness Mucositis 
Week-1 
       
Week-2 
       
Week-3        
Week-4        
Week-5        
Week-6 
       
 
 
 
 
 
 
PROFORMA – VII 
PATIENT EDUCATION FORM 
1) Do you know about cancer? 
 a) Yes     b) No 
     If yes, what do you know about cancer? 
 a) Malignant tumor   b) Benign tumor 
 c) Malignant and metastasis d) others 
2) Do you have any of these social habits? 
 a) Tobacco    b) Alcoholic 
 c) Smoking             d) None 
3) Do you have any of these social habits? 
 
            a) Yes                                b) No  
 
4) What are the treatments available for cancer? 
 a) Radiotherapy   b) Chemotherapy 
 c) Surgery    d) Combination of any of the     
                                                                        above (a/b/c) 
 
5)  Do you know about the Radiotherapy treatment? 
 a) Yes    b) No 
 
6)  Do you know that you have to attend the radiotherapy regularly 
as per doctor’s advice? 
 a) Yes     b) No 
7)  Do you know that radiotherapy interruption would delay up the 
effectiveness of your treatment? 
 a) Yes   b) No 
8) Are you aware of the side effects of the Radiotherapy treatment? 
 a) Yes     b) No 
     If yes, who told you? 
 a) Doctor                 b) Pharmacist 
     c) Nurse             d) Others 
9)  Do you know that Skin Dermatitis is one of the side effects of the 
radiotherapy treatment? 
 a) Yes    b) No 
10) How will you manage the Skin Toxicities during radiation? 
          a)  By applying oil over the skin. 
          b)  By consulting doctor 
          c)  By using Amrad cream  
  d)  I didn’t follow any of these measures 
 
11)  Do you have any problems with Amrad cream? 
       a) Yes      b) No 
12)  Where do you store your medicine? 
        a)  Refrigerator      b) At room temperature        c) Anywhere 
13) Do you know how to use this cream? 
 a) Yes                     b) No 
14)  Do you know when to apply this cream? 
     a) Morning        b) Night    
c) Before radiation  d) at any time 
15) If you find any side effects while using this cream what will you  
           do? 
    a) I will inform to the doctor 
    b) I will stop the medication 
    c) I don’t know 
    d) I will choose alternative myself  
16)  Do you have faith that your treatment would cure the disease? 
  a) Yes I have faith           b) No I don’t have 
 
 
17)   Are you following the doctor’s advice? 
       a) Yes        b) No 
18)  Are you following the dietary instructions such as taking rich 
fruit juices, soft foods and avoiding hot spicy foods properly? 
 a) Yes   b) No 
19)  Are you applying the Medication regularly? 
           a)  Yes                      b) No 
 
20)      Do you check the expiry date while purchasing the medication? 
  a) Yes  b) No 
21)  Do you think that the benefit supersede the cost of the 
treatment? 
        a) Yes                     b) No 
22)    Do you know that there is greater chance of recurrence of 
cancers and that   regular follow-up visit is vital?  
 a) Yes   b) No 
 
 
